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Abstract 
The Hippo pathway is a key regulator of cell survival, proliferation and tissue 
homeostasis. In addition, it is vital for development and regeneration. The activity of 
the Hippo pathway depends on intra- and extra-cellular signals and is tightly regulated 
by diffusible chemicals as well as mechanical stimuli. The pathway comprises of a 
kinase cascade that controls the activity of YAP and TAZ, homologous transcriptional 
co-activators. Despite its central role in most cells the overall regulation of the Hippo 
pathway, especially originating from the plasma membrane, is not yet fully 
understood. Caveolae are 50-100 nm bulb-shaped plasma membrane invaginations 
that function in endocytosis, protection from mechanical stress and in cell signalling. 
Hence, the aim was to identify if caveolae and the Hippo pathway are functionally 
linked. This thesis reveals that the central caveolar components CAVEOLIN1 and 
CAVIN1 depend on YAP/TAZ. CAVEOLIN1 and CAVIN1 are direct YAP-TEAD target 
genes and YAP/TAZ are essential for the expression of caveolar components in 
mammalian cells and in zebrafish. Moreover, CAVEOLIN1 dictates YAP/TAZ 
subcellular localisation and inhibits their activity. Notably, in cells with diminished 
levels of caveolae, YAP/TAZ are hyperactive (nuclear), which led to increased 
induction of gene transcription. Finally, the activation of YAP/TAZ by shear stress is 
partly dependent on caveolae. These data link caveolae to Hippo pathway signalling 
in the context of cellular responses to mechanical stimuli and suggest feedback 
regulation between the Hippo pathway co-transcriptional activators YAP/TAZ and 
essential caveolae components. 
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Lay Summary 
The development of most organs and the specialisation and survival of each cell of 
an organism depends on signals that the cell receives. One signalling pathway which 
is central for many functions of the body is the Hippo pathway. This pathway is a key 
cellular control centre and its activity is influenced by various stimuli. An example is 
the flow of liquid, like the blood flow in our vessels. The cells lining our blood vessels 
experience friction on their outer membranous layer when the blood passes by them. 
Capable of sensing the liquid flow are little structures in the outer membrane layer of 
the cell which are called Caveolae. In Latin Caveolae mean “little caves”. They have 
the shape of tiny cups inserted into the membrane of the cell. This thesis investigates 
if there is a functional link between the Hippo pathway and Caveolae, especially when 
a cell senses and responds to liquid flow. 
One main discovery is that the Hippo pathway is important for the number of 
Caveolae. Consequently, only cells with a normal Hippo pathway contain 
physiological numbers of Caveolae. On the other hand, Caveolae were also 
discovered to influence the Hippo pathway activity. In the context of flow sensing, cells 
respond differently when they do not have a functional Hippo pathway and Caveolae. 
In normal cells, liquid flow strongly activates one part of the Hippo pathway, which 
induces the expression of genes and the secretion of molecules, which in turn 
activates neighbouring cells. In contrary, cells without Caveolae do not show this 
strong activation of the Hippo pathway as a response to liquid flow. Therefore, the 
Hippo pathway activation by liquid flow depends (at least partly) on Caveolae. As the 
Hippo pathway and Caveolae are both important for the development of blood 
vessels, their interaction might be central of the maintenance and renewal of blood 
vessels. 
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In conclusion, the interplay between the Hippo pathway and Caveolae is a new insight 
into how cells react to liquid flow and provides a new mechanism on how cells respond 
to mechanical stimuli in general. Consequently, future studies should focus on 
investigating the underlying mechanisms of the interaction between the Hippo 
pathway and Caveolae in order to pave the way for the development of new 
diagnostics and therapies in the cardiovascular field. 
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1. Introduction 
1.1 The Hippo Pathway 
1.1.1 Discovery of the Hippo pathway 
The Hippo pathway is a key regulator of cell survival, development, regeneration and 
tumorigenesis [1, 2]. The first component of the pathway was discovered in Drosophila 
in 1995, when loss-of-function mutation of the one of the key kinases (Warts or Lats) 
resulted in accelerated proliferation and decreased cell death [3, 4]. However, it was 
only in the early 2000s that more components of the Hippo pathway, including the 
Hippo kinase (MST1/2 in mammals), were discovered [5-12]. With the identification of 
the Drosophila Yorkie (and mammalian YAP) and later transcription factors Scallop 
(Drosophila) and TEAD (mammals) the missing links between Warts/LATS and gene 
transcription were discovered and the combined realisation of the core Hippo pathway 
was established [13-19]. Since its discovery the Hippo pathway has been shown to 
be greatly conserved in a wide range of species, including mammals [7, 20], and the 
list of Hippo pathway components and interactors is constantly growing. 
 
1.1.2 The role of YAP and TAZ as transcriptional 
regulators 
The Hippo pathway regulates the phosphorylation and, thereby, the subcellular 
localisation of the co-transcriptional activators YAP/TAZ [21]. When the Hippo 
pathway kinase cascade is inactive, YAP/TAZ remain unphosphorylated and are 
therefore activated [7]. YAP (yes-associated protein) and its paralogue TAZ/WWTR1 
(transcriptional coactivator with PDZ-binding motif or WW-domain containing 
 Introduction 
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transcriptional regulator 1) are homologs to the Drosophila Yki (Yorkie) [13, 15, 22]. 
YAP and TAZ are multi-domain proteins with several protein binding interfaces (Figure 
1), e.g. WW domains or conserved phosphorylation sites [23]. 
 
 
Figure 1: Diagram of YAP and TAZ proteins. 
Representation of important regions and interaction sites of the isoforms 1 of 
both YAP and TAZ. Please refer to text for more details. Adapted from Chen, et 
al. [23]. 
 
Activated YAP and TAZ translocate into the nucleus, where they bind transcription 
factors like RUNX, SMAD and, mainly, TEADs (TEA domain transcription factor 1 - 4) 
[14, 15, 24]. As YAP/TAZ lack intrinsic DNA-binding regions, they depend on 
transcription factors to regulate gene transcription [14-16]. Essential for YAP/TAZ and 
TEAD interactions are serine residues in the highly conserved N-terminus of YAP/TAZ 
at the positions S94 for YAP and S51 for TAZ (Figure 1). YAP/TAZ interact with the 
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C-terminus of TEADs and form hydrogen bonds with tyrosine residues, for example 
at Y406 or Y421 of TEAD1 or Y429 of TEAD4 [15, 17, 18, 25, 26]. The YAP/TAZ-
TEAD complexes then bind to M-CAT (muscle-specific cytidine-adenosine-thymidine 
sequence) and putative TEAD binding DNA motifs with the core sequence 5’-
GGAATG-3’ in both promoter and enhancer regions [26-29]. The YAP/TAZ-TEAD 
interactions induce expression of genes facilitating proliferation and inhibiting 
apoptosis, including connective tissue growth factor (CTGF) and cysteine rich 
angiogenic inducer 61 (CYR61) [15, 30].  
 
1.1.3 LATS1/2-mediated YAP/TAZ inhibition  
The activation of the Hippo pathway kinases large tumour suppressors 1/2 (LATS1/2) 
leads to the inhibitory phosphorylation of YAP/TAZ serine residues in their HxRxxS 
motifs (Figure 1) [22, 31, 32]. In the most common mammalian YAP isoform (#1) there 
are five conserved serine residues, S61, S109, S127, S164, S381, while TAZ (#1) is 
phosphorylated by LATS1/2 at S66, S89, S117 and S311 [22, 31, 33]. The YAP S127 
is central to LATS-induced phosphorylation [31]. The LATS-mediated phosphorylation 
of YAP/TAZ is a signal for the interaction of YAP/TAZ with the phosphor-binding 14-
3-3 protein family, resulting in their cytoplasmic sequestration and subsequent 
degradation [31, 34-36]. In YAP, phosphorylation at S381 is an important signal for 
ubiquitination. In TAZ the LATS1/2-mediated phosphorylation of S311 induces the 
phosphorylation at S314, which is a signal for TAZ ubiquitination. Therefore, LATS-
induced YAP S381 and TAZ S311 phosphorylation (Figure 1) are markers of 
decreased YAP/TAZ stability Figure 1[34, 35]. In summary, the activity of the Hippo 
pathway results in YAP/TAZ inactivation and inhibition of YAP/TAZ-induced gene 
transcription.   
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1.1.4 The Hippo pathway core kinase cascade 
The mammalian Hippo pathway core kinase cascade (Figure 2, in purple) comprises 
of the Ste20-like kinases 1/2 (MST1/2), which upon phosphorylation interact with and 
phosphorylate Salvador Family WW Domain Containing Protein 1 (SAV1) [6, 37]. 
Active MST1/2 further phosphorylate MOB kinase activator 1A/B (MOB1A/B) [38]. 
Both SAV1 and MOB1A/B act as scaffold proteins to facilitate the recruitment and 
activating phosphorylation LATS1/2 by MST1/2 [39, 40]. 
 
 
Figure 2: The Hippo pathway. 
Simplif ied scheme of the interactions of (canonical , in purple) Hippo pathway 
components differentiating between the “on” stage, with the active kinase 
cascade, and the “off” stage ,  with no inhibitory phosphorylation of YAP/TAZ.  
MAP4K and NDR1/2 are exemplary for additions to the canonical Hippo kinase 
cascade. The SRC-mediated phosphorylation of YAP/TAZ is outlined to indicate 
one of the established Hippo pathway-independent activation mechanisms of 
YAP/TAZ. For details, please see text.  Figure generated using BioRender.  
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An important upstream regulator of the Hippo pathway core kinase cascade is the 
tumour suppressor Neurofibromin 2 (NF2 or Merlin) [40, 41]. NF2 induces the 
phosphorylation of LATS1/2 by recruiting them to the plasma membrane where 
LATS1/2 are phosphorylated by MST1/2, which is accumulated at the plasma 
membrane due to the binding of SAV1 [40]. Activation of the Hippo pathway kinase 
cascade leads to the phosphorylation and inhibition of the transcriptional co-activator 
YAP and TAZ [13, 15, 22]. 
 
1.1.5 Expansion of the Hippo Pathway 
In recent years an expansion of the Hippo pathway has occurred. Various effectors 
alter the response of Hippo pathway components. Besides MST1/2, more recently the 
MAP4Ks (mitogen-activated protein kinase kinase kinase kinase; MAP4K1/2/3/5 and 
MAP4K4/6/7) are now established LATS1/2 activating kinases (Figure 2) [42-45]. 
Potentially, NF2 mediates LATS1/2 phosphorylation, by-passing MST1/2 by activating 
MAP4Ks [21, 40, 42].  Recently, the Serine/Threonine Kinase 25 (STK25) has been 
confirmed as another mechanism of LATS1/2 phosphorylation [46]. STK25 mediates 
phosphorylation of LATS1/2 and presents a new way of upstream YAP/TAZ regulation 
[46]. Moreover, LATS1/2 are not the only members of the NDR (nuclear Dbf2 related) 
kinase protein family capable of phosphorylating YAP (Figure 2) [39, 43]. NDR1/2 
(also known as STK38/STK38L) are highly conserved across species [47, 48]. NDR1 
has been shown to be phosphorylated and therefore activated by MAP4K4 [49]. 
NDR1/2 phosphorylate YAP in a similar way to LATS1/2 and although NDR1/2 have 
not yet been proven to phosphorylate TAZ, they provide a LATS1/2-independent and 
therefore parallel regulation of YAP activity [43, 50]. The complexity and redundancy 
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of YAP/TAZ regulation enables the Hippo pathway to robustly respond to a large 
variety of stimuli in a timely, context and spatially specific manner. 
Moreover, the classical view of YAP/TAZ being inhibited by phosphorylation is not 
clear cut. YAP was originally identified as a SRC interacting protein [16]. SRC-induced 
phosphorylation of YAP (at tyrosine 341, Y357 and Y394) and TAZ (at Y361) is 
activating (Figure 2) [51, 52]. In addition, SRC was shown to inhibit LATS 
phosphorylation and therefore activates YAP/TAZ via two different mechanisms [53, 
54]. Finally, it is worth noting that TEAD transcription factors are not only regulated by 
the Hippo pathway, but also play a role in other signalling pathways like the Wnt 
pathway [55]. Likewise, YAP/TAZ regulate gene transcription not exclusively via 
TEADs [24, 25]. One example is YAP being a co-transcriptional activator for p73 to 
induce apoptosis [56, 57]. Consequently, accumulating research findings are 
constantly adding complexity to this central signalling pathway. 
 
1.1.6 The Hippo Pathway: Function and Pathology 
Since its discovery, the central role of the Hippo pathway as a regulator of essential 
functions in the cell and whole organisms became more and more apparent [58]. The 
importance of YAP and TAZ for the organism has become evident by knockdown and 
knockout models showing dramatic phenotypes [59]. Although YAP and TAZ have a 
large number of overlapping functions and in most cases compensate for each other, 
they are overall not interchangeable [60]. The phenotypes of knockout animals differ 
largely depending on which of the two co-transcriptional activators is affected. The 
YAP knockout in animals is lethal (in mice at E8.5), and leads to a shortened body 
axis and aberrant yolk sac vasculogenesis as well as increased body curvature in 
zebrafish [59, 61, 62]. Taz (Wwtr1) knockout mice on the other hand are viable and 
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reach adulthood. However, they die earlier than WT mice as a result of end stage 
kidney disease caused by renal cysts [63]. Yap/Taz double KO mice are not viable 
and die before the morula stage [64]. Due to severe consequences on the 
development and viability the effects of Yap/Taz double knockout in mice is 
investigated in inducible systems or conditional KO. In zebrafish, yap/taz knockout 
shows sever inhibition of posterior body elongation and leads to death at an early 
somitogenesis stage [65, 66]. YAP/TAZ transcriptional activity strongly depends on 
the interaction with TEAD. Thus, point mutations in the TEAD genes, which inhibit the 
interaction with YAP/TAZ proteins, lead to disease development. One example is the 
missense mutation at Y421 in TEAD1, which leads to Sveinsson’s chorioretinal 
atrophy resulting in bilateral chorioretinal degeneration [17]. The deficiency of 
YAP/TAZ is detrimental while their hyperactivation in certain circumstances is 
potentially beneficial for the organism. For example, studies in the liver and heart 
showed that the induction of Yap/Taz activity can facilitate organ regeneration [67-
69]. After partial hepatectomy, Yap activity increases, which leads to increased 
proliferation of hepatocytes, whereby the liver regains its original size [19, 70]. 
However, persistent YAP hyperactivation causes tumour development in multiple 
organs, including the liver [19, 68]. In general, YAP/TAZ hyperactivation, e.g. by loss-
of-function mutations of components of the kinase cascade, is linked to tumour 
formation and progression [71]. However, intriguingly, only loss-of-function mutations 
of NF2 occurs frequently in a subset of cancers [72]. NF2 loss leads to YAP/TAZ 
hyperactivation, which results in disease onset and progression in malignant 
mesothelioma (prevalence of 40-50%) and schwannoma [72-74]. Increased YAP/TAZ 
activity is identified in most types of solid tumours, including cancers of the lung, 
breast and the gastrointestinal tract [75]. 
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The stiffness of cancerous tissues differs from that of healthy tissues and this change 
affects YAP/TAZ activity [76, 77]. The Hippo pathway, in general, responses to 
alterations of the extracellular matrix (ECM) compositions [76-78]. Increased stiffness 
of the extracellular environment triggers a mechanotransductive response of 
YAP/TAZ and induces their activity [77]. The response of YAP/TAZ to changes of the 
ECM is linked to the actin cytoskeleton and cell tension, which is key in healthy tissues 
as it allows YAP/TAZ activation during cell proliferation [77, 79-81]. However, in 
fibrotic lungs, for example, increased ECM deposition induces nuclear accumulation 
and activation of YAP/TAZ in fibroblasts, which results in a self-sustaining fibrogenic 
feed forward loop [82]. Thus, a tight and dynamic regulation of the Hippo pathway is 
needed to maintain tissues homeostasis and allow controlled regenerative processes. 
 
1.1.7 Regulation of the Hippo Pathway 
Due to the central role of the Hippo pathway for multiple cellular processes a flexible 
and tight regulation of the Hippo pathway is indispensable [21, 83, 84]. The pathway 
is regulated by both soluble ligands and mechanical stimuli, and the cytoskeleton 
plays central roles in mediating these responses [2, 71, 77, 80, 85, 86]. Nevertheless, 
the complexity and context dependency of Hippo pathway regulation remains to be 
fully elucidated. One example, highlighting the increased molecular understanding of 
the regulation of the complex Hippo pathway, are G-protein-coupled receptors 
(GPCRs) [87]. Depending on the coupled G-protein, LATS1/2 are activated or 
inhibited. For example, the Gα proteins G12/13 are activated by soluble cues (i.e. 
serum-borne lysophosphatidic acid (LPA) and sphingosine-1-phosphophate (S1P) 
exposure) and inhibit LATS1/2, which results in YAP/TAZ activation [87, 88]. On the 
contrary, stimulation of GPCR with epinephrine or glucagon via GαS actives LATS1/2 
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and leads to the phosphorylation and inactivation of YAP/TAZ [87]. Besides chemical 
cues, mechanical stimuli are central for the Hippo pathway and YAP/TAZ activity 
regulation. Those stimuli can be cell intrinsic or extracellular. Small GTPases regulate 
cytoskeletal dynamics, which in turn influence YAP/TAZ [89]. For example, the RhoA 
GTPase activates YAP/TAZ by interfering with the activity of the YAP/TAZ inhibitor 
AMOT. RhoA stabilises the interaction between F-actin and AMOT, which blunts the 
activity of AMOT. On the other hand, RhoA facilitates the AMOT-induced inhibition of 
NF2 [89, 90]. Furthermore, cell morphology dependent F-actin stress fibre 
organisation regulates YAP/TAZ localisation. At low cell density cells are spread and 
flat and contain many F-actin fibres, while high density cells are more compact and 
stress fibres are reduced. F-actin fibres induce LATS1/2 activity and therefore 
YAP/TAZ inactivation [86, 91]. The regulation of the Hippo pathway activity by contact 
inhibition is a mechanism that contextually controls cell proliferation and tissue size 
[31, 80]. Finally, the crosstalk between the Hippo pathway, YAP/TAZ and focal 
adhesions (FA) is a mechanism that allows the cell to sense and respond to multiple 
mechanical stimuli [79]. YAP/TAZ, for example, regulate FA via activation of Rho-
GTPases, which are also integral parts of FA assembly and stability [77, 91]. Integrins 
are essential FA components and are partly regulated by YAP/TAZ-TEAD. 
Consequently, loss of YAP/TAZ-TEAD activity dramatically changes the overall 
cellular composition of integrins [15, 79]. Furthermore, YAP deficiency is associated 
with disrupted integrin subunit interaction which results in a reduction of FA number 
[79]. Another consequence of loss of YAP activity is the reduction of expression of FA 
components vinculin and zyxin, important components mediating linkage of FA with 
the cytoskeleton [79]. Thus, YAP/TAZ activity is important for FA integrity and the 
interaction between FA and the cytoskeleton [79]. Besides FA other plasma 
membrane elements are interacting with YAP/TAZ, like primary cilia, clathrin-coated 
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pits, clathrin plaques as well as, revealed in this thesis, caveolae. The interaction with 




1.2.1 Discovery and Abundance of Caveolae 
With the advances in electron microscopy mid of the past century, caveolae structures 
were first described in 1953. The flask-like membrane invaginations discovered in 
heart endothelium were named plasmalemma vesicles [92, 93]. Two years later the 
name caveolae, Latin for “little caves” (intracellulares) was used for the first time when 
describing those uncoated plasma membrane structures found in gall bladder 
epithelium [92, 94]. The original focused investigations of caveolae were performed 
by the group, which discovered them, and they concluded that caveolae are part of 
the endocytic system of the cell [93]. However, it was only in 1992 that CAVEOLIN1 
(CAV1) the main structural component and molecular marker of caveolae was 
discovered [95]. Today, caveolae are no longer seen as key for bulk steady state 
endocytosis, but are recognised as pleomorphic multifunctional plasma membrane 
domains [96]. 
Caveolae are 50-100 nm bulb-shaped structures formed by a 70S complex of protein 
components (CAVEOLIN1-3 and CAVIN1-4 proteins) (Figure 3) as well as various 
lipid components (cholesterol and glycosphingolipids) [97-99]. The 
CAVEOLIN/CAVIN oligomere form tissue specific caveolar complexes, which are 
central for the biogenesis of caveolae. Depending on the cell type, caveolae are 
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formed by different proportions of CAVEOLIN and CAVIN complexes [98, 100, 101]. 
CAVEOLIN3 (originally named M-Caveolin) and CAVIN4 are muscle specific caveolar 
proteins [98, 101]. CAV1 is essential for caveolae formation in non-muscle cells, 
whereas CAVIN1, formally known as polymerase I and transcript release factor 
(PTRF), is critical for caveolae formation throughout [102-105]. Furthermore, the 
overall abundance of caveolae varies significantly not only between healthy and 
cancerous cells but also between cell types [106]. Caveolae are hardly found in 
hepatocytes and not present in the kidney proximal tubule [107, 108]. However, they 
are highly abundant in endothelial cells, adipocytes and myocytes, where they make 
up large parts of the plasma membrane, pointing towards their increased functional 
importance for specific cell types [102, 109, 110]. 
 
 
Figure 3: Caveolae. 
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Structure of caveolae and interactions of caveolar components with cytoskeletal 




1.2.2 The Caveolae Structure 
The main caveolae components, CAVEOLINs, are integral membrane proteins with 
both their C- and N-terminal region localised in the cytoplasm [96]. CAVEOLINs have 
four distinct protein regions; the N-terminus, a conserved scaffolding region, an 
intramembrane domain as well as the C-terminus, which forms a hairpin structure in 
the membrane [112]. CAV1 hetero-oligomerises with CAV2 in the Golgi and this 
complex is transported to and fused with the plasma membrane [113-115]. The C-
terminus of CAV1 is palmitoylated while its N-terminus is regulated by SRC-mediated 
phosphorylation (at tyrosine14) [116, 117] (Figure 4). Cav1 by itself is capable of 
forming caveolae-like structures in bacterial systems [118]. 
 
 
Figure 4: Representation of CAVEOLIN1. 
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A:  Scheme of the CAVEOLIN1 protein domains. B: Membrane localisation of 
CAVEOLIN homodimer in the plasma membrane. Please see text for details. 
Adapted from Lobos-Gonzalez, et al.  [119]. 
 
 
However, in mammalian cells and in vivo CAVIN proteins (CAVIN1 in particular) are, 
essential components of the caveolae bulb [103, 104, 120, 121]. Notably, the stability 
of CAVIN proteins in non-muscular derived cell types depends on CAV1 expression, 
CAV1 stability likewise dependents on CAVIN1 expression, indicating the co-
dependence of CAV1 and CAVIN1 for caveolae structures [102, 103, 105]. CAVINs 
form several distinct heterocomplexes, which associates with caveolae to facilitate 
the stability of the caveolae bulb [102, 122-125]. CAVIN2-4 are CAVIN1 homologs 
and associates with caveolae only in the presence of CAVIN1. CAVIN2 has high 
membrane affinity and facilitates stabilisation of CAVIN1 at the plasma membrane 
[125]. At the neck of caveolae structures EHD (epidermal growth factor receptor 
substrate 15 [Eps15] homology-domain-containing) accumulate (Figure 3) [126-128]. 
There is a high sequence similarity between EHD1-4, however, it is EHD2, which the 
most important EHD protein for promotion of caveolar clusters and the 
mechanoprotective abilities of caveolae [129]. Upon loss of EHD2 proteins, the 
structure of the bulb remains, however the morphology of the caveolar neck changes 
[126, 129]. In addition, EHD1, 3 and 4 accumulate at caveolae, especially in EHD2-
deficient cells, which might compensate for EHD2 loss [129]. Besides CAVEOLIN, 
CAVIN and EHD proteins, PACSINs (protein kinase C and casein kinase substrate in 
neurons proteins) are essential for caveolae stability and morphology. PACSIN2 (also 
known as SYNDAPIN2) has a BAR domain, which promotes the formation of 
membrane curvatures [101, 130, 131]. Knockdown of Pacsin2 results in the loss of 
caveolae structures in fibroblasts and epithelial cells, while knockout of Pacsin3 led 
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to a reduced number of caveolae in murine muscle cells [126, 130, 132]. In vertebrate 
cells, these caveolar components are spatially and timely coordinated in order to 
ensure caveolae formation and stability [96]. Good progress has been made on the 
molecular details of how these caveolar protein complexes are formed [96, 99, 123], 
however in great part the biological functions of caveolae and the distinct components 
of the CAVEOLIN and CAVIN complexes are still not well understood.  
 
1.2.3 Caveolae: Function and Pathology 
Caveolae are involved in a large variety of processes. They function in endocytosis, 
maintenance of the membrane lipid composition and are involved in signalling. 
Moreover, caveolae are central for mechanosensing and protection from mechanical 
stress [133, 134]. 
Although initially described as endocytic elements caveolae do not appear to be 
crucial cargoes for substances and plasma membrane components within the cells 
[97]. It is speculated that endocytosis performed by caveolae facilitates the recycling 
and a dynamic adjustment of caveolae abundance at the plasma membrane [96]. 
Moreover, as highly specialised plasma membrane domains, caveolae exhibit a 
specific profile of lipids compared to other regions of the membrane with increased 
glycosphingolipids and cholesterol content [135]. The palmitoylation sites CAV1 
possesses as well as its scaffolding domain are important for cholesterol binding [117, 
136-138]. CAVINs have lipid-binding properties themselves, e.g. binding of 
phosphatidylserine or phosphoinositide [124, 125, 139]. As a consequence, lack of 
caveolae results in different types of lipodystrophy [96]. Patients with non-functional 
CAV1 develop congenital generalised lipodystrophy (CGL), a rare genetic disorder, 
which is characterised with a nearly total loss of body fat [140]. Similarly, Cav1 KO 
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mice are leaner and have smaller adipocytes and lipid droplets emphasising the 
importance of Cav1 for lipid homeostasis [141]. In addition, the loss-of-function 
mutation of CAVIN1 is linked to lipodystrophy in patients [142]. 
Caveolae interact with various signalling pathways. They play roles in cell growth, 
migration, survival and death as well as various cancer-associated processes [143]. 
The main caveolae component, CAV1, for instance has been reported to interact with 
the K-RAS oncogene, Rho GTPases, G proteins and their receptors as well as a 
range of kinases, like SRC or protein kinase A [144-148]. However, detergent 
insolubility and the resistance to extract caveolae without harsh detergents, make 
interaction studies challenging [134, 149]. Only recently the in vitro analysis of isolated 
caveolae was successful and promises new insight into the interactome of caveolae 
[150].  
Mechanical stress triggers remodelling of the actin cytoskeleton and the plasma 
membrane. Caveolae provide membrane plasticity, which allows the cell to 
accommodate changes in tension [111]. The membrane invaginations associate with 
actin stress fibres, which regulate their organisation and trafficking [95, 111, 151-153]. 
The significance of the cytoskeleton for caveolae is indicated by the fact that caveolar 
curvature depends, besides on cholesterol, on stress fibres [95, 111, 154, 155]. An 
excess in stress fibres leads to increased membrane tension and is accompanied by 
increased accumulation of CAV1 at the plasma membrane as well as caveolae 
flattening [151, 156, 157]. The physical interaction of caveolae and stress fibres is 
assumed to depend at least partly on the actin cross linker filamin A [155, 158, 159]. 
Besides Filamin A, EHD2 might be another element linking caveolae with stress fibres 
as EHD2 silencing increases CAV1 motility [127]. Another protein which is localised 
at the neck of caveolae is DYNAMIN2 (DYN2). It regulates actin polymerisation and 
caveolar endocytosis [151, 152, 160]. Furthermore, CAV1 activates RhoA and 
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therefore a signalling pathway which is central for mechanotransduction and the 
control of actomyosin contractility [111, 161]. RhoA mediates force-induced 
cytoskeletal reorganisation, a process which requires CAV1 [162]. RhoA silencing 
results in reduced alignment of stress fibres with CAV1 [152]. Thus, caveolae are 
tightly interlinked with the cytoskeleton to sense and regulate responses to 
mechanical stimuli. One cell type which experiences persistent mechanical stress and 
shows a high abundance of caveolae are endothelial cells. For example, up to 70% 
of the plasma membrane in alveolar endothelium is covered by caveolar [163-165]. 
CAV1 is a key feature of the vascular system, where it plays a role in the nitric oxide 
pathway to regulate contractility of vessels and capillary tubule formation [98, 166-
168]. As a consequence, it is not surprising that upon loss of Cav1, mice develop 
hypertrophic cardiomyopathy leading to heart failure as well as lung fibrosis with 
pulmonary arterial hypertension (PAH) [140]. In the endothelium, CAV1 deficiency 
induces a constitutive hyperactivation of the nitric oxide pathway, which is important 
for regulation of blood pressure [169, 170]. Therefore, the high number of caveolae in 
endothelial cells is not coincidental. The blood flow in vessels exhibits a constant 
mechanical force on the endothelium, termed shear stress. In this process, caveolae 
do not only influence the remodelling of blood vessels but also harbour 
mechanoprotective properties [110, 171-173]. Under severe cell stretching caveolae 
appear to flatten in order to increase the surface to volume ration of the cell and 
therefore protect the cell from bursting [174]. Upon flattening of the caveolae bulb 
caveolar components, e.g. CAVINs and EHDs, are released from the bulb into the 
cytoplasm [109, 173, 174]. Part of dissociated EHD2 accumulates in the nucleus and 
induces transcription of genes involved in receptor interactions with the extracellular 
matrix (ECM) as well as genes of the TNF-α or K-Ras pathways [153, 175]. 
Cytoplasmic CAVIN complexes interact with CAVEOLIN complexes at the plasma 
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membrane and regenerate the full morphological caveolae structures [153]. Caveolae 
influence the composition and homeostasis of the ECM. Cav1 knockout in mammary 
glands induced the expression of ECM components, e.g. fibronectin and collagen, 
resulting in an increased ECM stiffening [176]. Deficiency of Cavin1 in adipocytes also 
increased the expression of fibronectin and collagen [177]. Similar results were 
obtained in murine fibroblasts, when Cav1 knockout induced elastin and collagen 
expression [178]. This can, at least partly, be explained by the co-dependence of 
protein stability between CAV1 and CAVIN1, as the deficiency of CAV1 destabilises 
CAVIN1 [102, 105, 125]. As a consequence, Cav1 KO mice show increased 
prevalence of lung fibrosis due to the fact that Cavin1 no longer inhibits collagen and 
fibronectin expression  [179]. Accordingly, CAVIN1 loss-of-function mutation leads to 
cardiac fibrosis as well as morphological and functional impairments of the lung and 
muscular dystrophy [142, 180, 181]. Also, dysregulation of CAVEOLIN3 expression 
is characteristic in different muscle disease phenotypes, e.g. limb gridle muscular 
dystrophy, rippling muscle disease, hyperCKemia, cardiomyopathy, distal myopathy 
or Duchenne muscular dystrophy [167, 182, 183]. Furthermore, CAVEOLIN3 was to 
be central for myotube formation and is therefore functionally important in skeletal 
muscles [184]. In conclusion, caveolae are distinctive versatile and pleomorphic 
plasma membrane organelles, which enable the cell to respond to a large variety of 
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1.3 Mechanotransduction 
1.3.1 Types and Functions of Mechanotransduction 
Cells constantly experience at least one type of mechanical force, as they are 
exposed to gravity, adhesion, pressure, tension or shear stress. These physical 
stimuli trigger cellular reactions allowing the organism to respond and adapt to 
changes of their environment [185]. The translation of physical forces into biochemical 
signals by a tightly structured signalling network is called mechanotransduction [185-
187]. The cellular response is diverse and ranges from proliferation and angiogenesis 
to differentiation and apoptosis [186, 188, 189]. Flow and shear stress are major forms 
of mechanical cellular stimuli. The blood flow in vascular systems exposes endothelial 
cells to stretching forces, hydrostatic pressure and most importantly tangential forces 
in the form of shear stress [190]. Flow is predominantly considered laminar, without 
turbulences or mixture and occurs mostly in straight arterial regions. On the other 
hand, turbulent or oscillatory flow occurs in branched or curved vessels and induces 
besides laminar also random movements [190]. Shear stress is the frictional force in 
the endothelium generated by blood flow and expressed in force-area unit (Dyn/cm2). 
The strength of shear stress strongly depends on the vessel type and the quality of 
flow, ranging for example from one Dyn/cm2 in smaller venous areas to 30 Dyn/cm2 
in greater arteries [191]. As the quality of shear stress is so variable a timely and 
adaptive response is needed. This cellular response is achieved by a wide range of 
sensors and integrative pathways that coordinate subcellular signalling processes 
[185]. In endothelial cells a range of proteins and plasma membrane domains are 
central mechanosensors and are capable in adapting to changes in shear stress; 
examples are adhesion molecules like PECAM1 (Platelet Endothelial Cell Adhesion 
Molecule 1), receptor 2 for VEGF (Vascular Endothelial Growth Factor), ion channels 
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and caveolae [192, 193]. Moreover, shear stress affects the cytoskeleton, which by 
itself may act as a mechanosensor and transducer enabling the cell to sense and 
respond to complex mechanical stimuli [165, 189]. 
 
1.3.2 Mechanotransduction: A Possible Link Between 
the Hippo Pathway and Caveolae 
Both the Hippo pathway and caveolae are regulated by mechanical stimuli, including 
shear stress [21, 58, 78, 194]. Importantly, how mechanical signals are sensed at the 
plasma membrane and transduced via the Hippo pathway is currently not well 
understood. As caveolae are important mechanosensors and protectors, further 
understanding of their overall function as mechanotransducers, including the 
downstream effectors are warranted [96, 111]. Since both the functional regulation of 
the Hippo pathway and caveolae are still not fully understood, I sought to investigate 
whether the Hippo pathway and caveolae are functionally integrated in the process of 
sensing shear stress. Elucidating the regulation of the Hippo pathway of and by 
caveolae in connection to mechanical stimuli reveals insights into clinically important 
processes and enhances our knowledge of tissue growth dysregulation and 
differentiation.
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2. Hypothesis and Aims 
 
Given that both the Hippo pathway and caveolae are capable of sensing mechanical 
stress, the central hypothesis of this thesis is that there is a mutual, regulatory 
interaction between caveolae and the Hippo pathway which impacts the ability of 
cells to sense shear stress. 
 
Consequently, this thesis aims to: 
1. Assess whether components of caveolae and their abundance depend on 
     YAP/TAZ 
2. Determine whether YAP/TAZ activity is influenced by caveolae 
3. Determine the potential regulation of YAP/TAZ by caveolae in the response 
     to shear stress 
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3. Materials and Methods 
Parts of this section have been taken from Rausch, et al. [195] and adapted with the 
consent from authors. 
 
3.1 Mammalian Cell Culture and Cell Lines 
3.1.1 General Cell Culture 
All cell lines were cultivated at 37°C in a humidified, 5% CO2 atmosphere. HEK 293A, 
HEK 293T and U2OS cells were cultivated in high glucose DMEM (Gibco) 
supplemented with 1% penicillin/streptomycin (v/v), 2 mM glutamine, and 10% fetal 
bovine serum (FBS) unless stated otherwise. The HEK 293A and HEK 293T cell lines 
are human epithelial cells originating from embryonic kidney of a female. The 
wildtypes (WT) as well as the HEK 293A YAP/TAZ and LATS1/2 double knockout cell 
lines were kindly provided by Professor Kun-Liang Guan lab, University of California, 
San Diego (UCSD) [196, 197]. HEK 293A cell lines were used to perform experiments 
while HEK 293T cells where used for virus generation. The U2OS cell line originates 
from human epithelial from the bone of a female suffering from osteosarcoma. The 
U2OS wildtype was kindly provided by Professor Jack Dixon (UCSD). Cells were 
periodically tested with the MycoZap kit (Lonza, cat# LT07-818) by A.F. Howie 
(University of Edinburgh, UoE) for mycoplasma contamination but were not 
authenticated. 
Generation of Stable Knockdown (KD), Knockout (KO) and Re-Expression Cell Lines 
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KD cell lines were generated by retrovirus mediated shRNA knockdown. The virus 
was generated in HEK 293T cells which were seeded into a 6-well the day before 
transfection to reach a confluency of about 70-80%. Using the GenJet transfection 
reagent (SignaGen Laboratories) the cells were co-transfected with pMD2G (200 
ng/well) and pSPAX2 (400 ng/well) plasmids (from the Kun-Liang Guan lab, UCSD) 
and with pKLO.1-vectors (400 ng/well) coding for shRNAs targeting YAP, TAZ and 
TEADs 1/3/4 (construct #1 and #2) [15, 197] as well as of CAV1 (construct #1 and 
#2) and CAVIN1 (construct #1 and #2), see Table 1. 
 
 Table 1: Constructs used for shRNA-mediated knockdown 
Construct Source Identifier 
pMD2.G Professor Kun-Liang Guan lab (UCSD) N/A 
pSPAX2 Professor Kun-Liang Guan lab (UCSD) N/A 
pLKO.1 Professor Kun-Liang Guan lab (UCSD) N/A 
shRNAScramble Sigma-Aldrich see [15] 
shRNA YAP Sigma-Aldrich TRCN0000300325 
shRNA TAZ Sigma-Aldrich TRCN0000370007 
shRNA CAV1 #1 Sigma-Aldrich TRCN0000007999 
shRNA CAV1 #2 Sigma-Aldrich TRCN0000008002 
shRNA CAVIN1 #1 Sigma-Aldrich TRCN0000430242 
shRNA CAVIN1 #2 Sigma-Aldrich TRCN0000446514 
shRNA TEAD1/3/4 
#1 and #2 
Professor Kun-Liang Guan lab (UCSD) see [15] 
All shRNA constructs carry the pLKO.1 backbone (puromycin selection) 
 
48 hours after transfection, the virus was harvested by aspirating and filtering 
(low binding syringe filters, Corning #431220) the medium of the transfected 
cells. The cells of interest were seeded the day before and the medium was 
exchanged with fresh 10 µg/ml polybrene containing medium shortly before 
adding 50-100 µl of virus solution to each well. Following a 6-8 hours 
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incubation the cell medium was changed. Stable cell lines were generated 
following puromycin (1 µg/ml) selection. 
The generation of CRISPR/Cas9-mediated KO cell lines is depicted in Figure 5. At 
first, two sets of complementary oligo nucleotides containing the sgRNA (single guide 
RNA) were annealed. Thereafter, they were ligated into a linearised pSpCas9(BB)-
2A-Puro (PX459 V2.0, Addgene #48139) plasmid at the BbsI restriction site, to 
generate the different KO vectors. The generated plasmids were inserted into Dh5α 
E.coli bacteria. After transformation separate bacteria colonies were picked and 
plasmids were extracted after propagation (as in 3.4.1). Vectors with the correct 
insertion of the sgRNA were identified by sequencing (performed by Source 
BioScience).  
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Figure 5: Generation of CRISPR/Cas9-mediated KO cell lines. 
For details on the procedure please refer to text. The generated DNA doubl e 
stand break (DSB) by the RNA-guided nuclease Cas9 is repaired mostly by non-
homologous end joining which can result in a nonsense mutation and the 
inactivation of the gene function, which equals a KO.  
 
Guide sequences were designed using http://crispr.mit.edu. For YAP and TAZ KO, 
previously generated constructs were used [197]. CRISPR sgRNA oligos are listed in 
Table 2. The CAV1 KO sgRNAs target sequences in the second exon of the human 
CAV1 gene (Figure 6). 
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Table 2: Guide sequences utilised for CRISPR/Cas9-mediated knockout (5’ → 3’) 
Target Forward Primer Reverse Primer 
CAV1#1 CACCGAGTGTACGACGCGCACACCA AAACTGGTGTGCGCGTCGTACACTC 
CAV1#2 CACCGTTTAGGGTCGCGGTTGACC AAACGGTCAACCGCGACCCTAAAC 





CACCGTCCATGGTGACGATCCTCA  AAACTGAGGATCGTCACCATGGAC 
 
 
Figure 6: Recognition site of the sgRNA for CRISPR/Cas9-mediated CAV1 KO. 
Representation of the human CAV1 gene. Dark grey: Exons. Light grey: Introns. 
Arrow: Localisation of the sequence complementary to the sgRNA oligoes  of 
CAV1#1 and #2 as in Table 2. 
 
Cells were transfected with the PX459 plasmid, containing the annealed 
sgRNA guide sequence, using LipoD293 or GenJet transfection reagent 
(SignaGen Laboratories). Clonal YAP, TAZ (WWTR1) and CAV1 KO cell lines 
were generated by transient transfection of CRISPR constructs, followed by 
two days of puromycin (1 µg/ml) selection and one day recovery in medium 
without puromycin. Subsequently, cultures were single cell sorted into 96-well 
plates by means of the BD FACS Aria II (with the assistance of the QMRI flow 
cytometry team, UoE) containing DMEM supplemented as above however with 
20% FBS to improve cell survival. Five to ten 96-well plates pre construct were 
prepared. Weekly, plates were checked for colony formation and evaporated 
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medium was replaced with fresh medium. After two to four weeks single cells 
formed colonies. Separately, colonies were detached from the 96-well plate 
using trypsin and 1/3 of the cell suspension was transferred into one and the 
remaining 2/3 were seeded into a second 24-well plate. In these two replicate 
plates single cell cultures were expanded and screened for positive knockouts 
by Western blot analysis. In detail, cells of one of the replica plates were 
prepared for protein lysates and expression of the protein of interest was 
analysed on a full-length Western blots, in order to check for truncated 
proteins, as in Figure 7. In addition, and if available, several antibodies 
recognising distinct parts of the targeted proteins were used. Positive knockout 




To generate U2OS CAV1 re-expressing cell lines, shCAV1 cells were transfected with 
CAV1-GFP plasmid (#14433, Addgene) and stable exogenous CAV1-expressing 
cells were established by G418-selection (1 mg/ml). Plasmids encoding either myc-
Figure 7: Example of KO 
clone screening. 
Example Western blot of 
the screening of CAV1 KO 
clones. Clone1 and 2 are 
potential CAV1 KO 
(indicated by arrow 
heads). Their cultures in 
the replica plate were 
expanded and used for 
experiments. HSP90 
served as loading control.  
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tagged WT or mutant YAP (S94A flag-tagged or 5SA myc-tagged) as well as flag-
tagged WT or mutant TAZ (S51A flag-tagged) are listed in Table 3. HEK 293A CAV1 
re-expressing cell lines were generated by lentiviral transduction of CAV1 KO cells 
with a pBabe vector carrying the open reading frame of human CAV1. Furthermore, 
HEK 293A LATS1/2 KO cells transfected with plasmids carrying LATS1 WT or K/R 
kinase loss-of-function mutant and cell lines were established by hygromycin B 
selection (4 µl/ml). Please note, the exogenously expressed constructs were not 
normalised to WT expression levels.  
 
Table 3: Re-expression plasmids used 
Target Source Identifier 
Cav1-GFP Originally from Ari Helenius (Addgene #14433) N/A 
pBabe-CAV1 This study (generated by GeneWIZ) N/A 
pBabe Addgene #1764 
CAVIN1-mCherry Doctor B. Nichols Lab Cambridge University see [125] 
pCMV Flag-YAP 





Professor Kun-Liang Guan lab, (UCSD) (Note, 
also encodes S128A, S131A, and S163A) 
(Addgene #48139) 
N/A 






Professor Kun-Liang Guan lab (UCSD) N/A 
pBabe-Flag TAZ 
(S89A) 
Professor Kun-Liang Guan lab (UCSD) N/A 
pQCXIH-HA 
LATS1 (WT) 
Professor Kun-Liang Guan lab (UCSD) N/A 
pQCXIH-HA 
LATS1 (K/R) 
Professor Kun-Liang Guan lab (UCSD) N/A 
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3.1.2 BOEC (Blood Outgrowth Endothelial Cells) 
Isolation, Differentiation and Culture of Primary 
Endothelial Cells 
Isolation of endothelial progenitor cells from human blood and subsequent 
differentiation was performed following a recently established protocol [198]. Briefly, 
60 ml of whole human blood were diluted 1:1 in phosphate-buffered saline without 
calcium and magnesium (PBS, Gibco), layered over a density gradient solution 
(Ficoll-Paque Plus, GE Healthcare) and centrifuged. The buffy coat and about 2/3 of 
the plasma were transferred into a fresh tube, diluted 1:1 with PBS and centrifuged. 
The resulting pellet was resuspended in 7.5 ml EGMTM-2 Endothelial Cell Growth 
Medium-2 (cat# CC-3162; complete, with 20% FBS and no penicillin/streptomycin) 
and seeded into a collagen-coated T75 flask (Corning, #354236). The medium was 
exchanged every other day until colonies became visible. 
Primary endothelial cells were cultured in T25 flasks (Corning, without additional 
coating) and kept in EGMTM-2 Endothelial Cell Growth Medium-2 and passaged once 
to twice a week. 
 
3.2 In vitro Assays 
3.2.1 Verteporfin Treatment of Cell Lines 
HEK 293A WT cells were seeded into 6-wells and the next day treated with 6.45 µM 
verteporfin (Sigma) with 1.87% (v/v) dimethyl sulfoxide (DMSO, Sigma) or DMSO 
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only. After 18 hours, mRNA was extracted using the RNase kit (QIAGEN, cat#74136), 
and RT-qPCR was performed as described in 3.3.2. 
3.2.2 Soft Agar Colony Formation Assay 
2x DMEM was supplemented with 20% FBS, 2% penicillin/streptomycin and 2% L-
glutamine. In 6-well plates (Corning) a bottom layer of 1% agarose (w/v in H2O) mixed 
1:1 with 2x complete DMEM was poured. For the top layer 5000 cells (per well) were 
added to 2x DMEM supplemented with 1.7 g/l NaHCO3 (Roth) and mixed with 0.7% 
warm agarose. The agarose cell mix was carefully pipetted on top of the bottom layer. 
After solidification at room temperature 0.5-1 ml of 1x complete DMEM was added 
per well. Cells were transferred to a cell incubator and cultivated under standard cell 
culture conditions. Medium was exchanged once to twice per week. Eight weeks after 
seeding cells were fixed and stained with 0.005% crystal violet in methanol 
(Thermofisher) overnight. After methanol-destaining of the agarose, abundance of 
colonies was documented by a Leica M205 fluorescence stereo-microscope at a 
magnification of 10x (for representation) and 50x (for quantification). The number of 
colonies (of at least 50 µm in diameter) per well were quantified manually by means 
of ImageJ and numbers of colonies were analysed using GraphPad (Prism). 
 
3.3 Molecular and Biochemical Assays 
3.3.1 Western Blotting 
Cell lysates were prepared by lysing cells in reducing lysis buffer (200 mM Tris pH6.8, 
8% SDS, 0.1% bromophenol blue, 40% glycerol, 20% beta-mercaptoethanol). 
Samples were hereafter transferred to a 1.5 mL Eppendorf tube and boiled at 95°C 
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for 10 min. If samples were not run straight away, they were stored at -20°C. SDS 
gels of a thickness of 1 mm were casted in glass plates. Resolving gels of 7-12% SDS 
were prepared by mixing 375 mM Tris (pH8.8), 0.1% (w/v) SDS, 0.1% (w/v) APS, 
0.08% (v/v) TEMED and the appropriate amount of water and acrylamide. Following 
polymerisation of the resolving gel, about 1 ml of stacking gel (composition as above, 
however at 5% SDS and made up with 520 mM Tris, pH6.8) was poured on top of it 
and a 15-well comb was inserted into the stacking gel before polymerisation. Samples 
were loaded onto the gels and the PageRuler pre-stained protein ladder (cat# 26616, 
Fisher Scientific) was used to determine protein sizes. Gels were run at 100V using 
the Bio-Rad system and running buffer (24.8 mM Tris, 189.5 mM Glycine, 0.1% [w/v] 
SDS). Subsequently, proteins were “wet” transferred onto a methanol-activated 
polyvinylidene difluoride (PVDF) membrane (Sigma). Pre-chilled (4°C) transfer buffer 
(25 mM Glycine, 190 mM glycine, 20% [v/v] methanol) was used and transfer was 
conducted at 0.5mA for 80 minutes in the cold room. The membrane was then 
incubated in 5% milk/TBS-T blocking solution (TBS-T: 20 mM tris [pH7.5], 150.6 mM 
NaCl, 0.1% [v/v] TWEEN20) for 45 minutes, briefly rinsed with TBS-T, cut and 
incubated with the appropriate antibodies (diluted in 5% BSA/TBS-T) overnight at 4°C 
at low agitation. Antibodies used for Western blotting are listed in Table 4. The next 
day membranes were washed in TBS-T for 2x 10 minutes and 1x 15 minutes. 
Followed by an incubation in HRP-conjugated secondary antibodies (listed in Table 
4) diluted 1:10,000 in 5% milk/TBS-T for 1 hour. After washing as above blots were 
developed using Immuno Western ECL mix (Millipore), X-ray films (SLS) and an X-
ray developer Ecomax (Photon imaging systems). Besides conventional SDS gels 
Western blotting was performed with Phos-Tag gels. Therefore, 15 μl Phos-Tag 
reagent (Wako chemicals) and 25 μl of 10 mM MnCl2 were added to each 7.5% (w/v) 
polyacrylamide gel while the subsequent steps remained the same. For densitometric 
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quantification of protein levels with ImageJ and the value of the protein of interest was 
normalised to the loading control of the same lane.  
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Table 4: Antibodies used for Western blotting 
Target Dilution Source Identifier 
Anti-YAP/TAZ 1:1000 Santa Cruz Biotechnology Cat# sc-101199 
Anti-CYR61 1:1000 Santa Cruz Biotechnology Cat# sc-13100 
Anti-CTGF 1:1000 Santa Cruz Biotechnology Cat# sc-14939 
Anti-GAPDH 1:10,000 Santa Cruz Biotechnology Cat# sc-25778 
Anti-CAV1 1:1000 BD Biosciences Cat# BD610060 
Anti-CAV2 1:500 BD Biosciences Cat# BD610684 
Anti-HSP90 1:10,000 BD Biosciences Cat# BD610418 
Anti-panTEAD 1:1000 Cell Signaling Technology Cat# 13295 
Anti-YAP p127 1:1000 Cell Signaling Technology Cat# 4911S 
Anti-YAP p397 1:1000 Cell Signaling Technology Cat# 13619 
Anti-NF2 1:1000 Cell Signaling Technology Cat# 6995S 
Anti-LATS1 1:1000 Cell Signaling Technology Cat# 3477 
Anti-LATS2 1:1000 Cell Signaling Technology Cat# 5888 
Anti-CAVIN1 1:1000 Cell Signaling Technology Cat# 69036 
Anti-YAP 1:1000 Abcam Cat# ab52771 
Anti-YAP (active) 1:1000 Abcam Cat# ab205270 
Anti-GFP 1:1000 Abcam Cat# ab6556 
Anti-CAVIN3 1:1000 Bethyl Cat# A302-419A 
Anti-CAVIN2 1:1000 Atlas Antibodies Cat# HPA039325 
Anti-Myc 1:1000 Cell Signaling Technology Cat# 2276 
Anti-VA-Cadherin 1:1000 Santa Cruz Biotechnology Cat# sc-1506 
Anti-PECAM1 1:1000 Cell Signaling Technology Cat# D87F2 
Anti-Goat IgG/HRP 1:10,000 DAKO Cat# P044901 
Anti-Rabbit IgG/HRP 1:10,000 DAKO Cat# P044801 
Anti-Mouse IgG/HRP 1:10,000 DAKO Cat# P044701 
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3.3.2 Quantitative Reverse Transcription PCR (RT-
qPCR) and Primers 
For RT-qPCR mRNA was extracted from cells using the RNeasy plus mini kit 
(QIAGEN) and quantified using the Nanodrop. Complementary DNA (cDNA) was 
generated using High-Capacity cDNA Reverse Transcriptase kit (Applied 
Biosystems). qPCR was performed on 1 ng of cDNA using the Brilliant III Ultra-Fast 
SYBR® Green QPCR Master Mix (Agilent Technologies) and the LightCycler® 96 
System (Roche) according to manufactures instruction. In mammalian cells 
expression levels of all genes analysed were normalised to Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT1) levels. Human specific primers (5 µM per primer 
per reaction) against YAP, TAZ, CYR61, CTGF, TEAD1, CAV1, CAVIN1 and HPRT1 
were used. Primer sets against caveolar components CAV1 and CAVIN1 were 
designed using primerbank [199], the remaining were taken from Hansen, et al. [197]. 
Methods to harvest and prepare cDNA from zebrafish embryos were performed by 
Jonathon R. Bostrom (Link lab, Medical College Wisconsin [MCW]) and have 
previously been reported [66, 200]. I performed the qPCR analysis zebrafish cDNA 
as described above, while expression levels were normalised to Elongation factor 1-
alpha (ef1a) [66]. Sequences of primers are listed in Table 5. 
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Table 5: Sequences of primers used for RT-qPCR (5’ → 3’) 
Target Forward Primer Reverse Primer 
CAV1 GCGACCCTAAACACCTCAAC ATGCCGTCAAAACTGTGTGTC 
cav1 fish CGATGTGGTGAAGGTGGACTTT TCAGCAGCCTGTAGCACCAAT 
CAVIN1 GAGGACCCCACGCTCTATATT CCCCGATGATTTTGTCCAGGA 
cavin1b 
fish 
AAACGTCTGGAGAGCAACGAGA GCCACA TTCACTTTCGAACCC 
CTGF CCAATGACAACGCCTCCTG TGGTGCAGCCAGAAAGCTC 
ctgf fish CTGCACAGCCAGAGATG CACTTCCCAGGCACTTT 
CYR61 AGCCTCGCATCCTATACAACC TTCTTTCACAAGGCGGCACTC 
cyr61 fish CCGTGTCCACATGTACATGGG GGTGCATGAAAGAAGCTCGTC 
ef1a fish TCTCTCAATCTTGAAACTTATCAATCA AACACCCAGGCGTACTTGAA 
TEAD1 ATGGAAAGGATGAGTGACTCTGC TCCCACATGGTGGATAGATAGC 




HPRT1 AGAATGTCTTGATTGTGGAAGA ACCTTGACCATCTTTGGATTA 
If not stated otherwise, primers are specific to human genes. All primers have been obtained 
from Integrated DNA Technologies, Inc. 
 
 
3.3.3 Chromatin Immunoprecipitation qPCR (ChIP-
qPCR) 
ChIP was performed on HEK 293A cells using the ChIP-IT® Express Enzymatic kit 
(Active Motif Inc.). For immunoprecipitation anti-mouse IgGs (#12102270, Fisher 
Scientific), anti-rabbit IgGs (#11805935, Fisher Scientific), anti-TEF-1 (TEAD1, 
#610923, BD Bioscience) and anti-YAP (ab52771, Abcam) antibodies were used. 
Subsequent DNA clean up (by DNA Clean & Concentrator™-5, Zymo Reseach) was 
followed by DNA quantification by qPCR analysis and output was normalised to the 
input DNA. Primers specific to sequence of the promoter of CAV1 promoter (CAV1 
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prom) or CAVIN1 promoter (CAVIN1 prom) as well as for regions within the genes, 
CAV1 in gene (CAV1 ingene) and CAVIN1 in gene (CAVIN1 ingene), were used to 
quantify the yield of the ChIP. CTGF (CTGF prom) was used as a control. For primer 
sequences please refer to Table 6. 
 
Table 6: Sequences of primers used for qPCR (5’ → 3’) (ChIP)  
Target Forward Primer Reverse Primer 
CAV1 prom TGGCATAACCTGTTGGCATA CCCAAACGCTTCGAAATAAG 











3.3.4 Proximal Promoter Cloning and Luciferase Assay 
The sequence of the upstream proximal promoter regions of CAV1 and CAVIN1 were 
obtained from http://genome.ucsc.edu and examined for M-CAT, muscle-specific 
cytidine-adenosine-thymidine sequence (CATTCC-A/T) and predominant TEAD 
binding site, and putative TEAD (G/A-G-A/T/C-ATG) binding motifs [201]. gDNA was 
isolated from MeT5A cells and used to amplify the sequences of the promoter regions 
of both CAV1 and CAVIN1 (primers see Table 7). pGL3-basic vectors carrying 
upstream proximal promoter regions of either CAV1 (-1800 to +200bp) or CAVIN1 (-
1250 to +150bp) were generated by restriction cloning and insertion into the multiple 
cloning site using Mlu1/Xho1 (CAV1) or Kpn1/Mlu1 (CAVIN1) respectively. A short 
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version (-500 to +200bp) of the CAV1 promoter was also generated, which does not 
harbour any predicted TEAD recognition sites. Sequences and orientation of the 
insert in the vector were verified by Sanger sequencing (performed by Source 
BioScience). HEK 293A YAP/TAZ KO cells were seeded into a 12-well plate (1x105 
cells/well) and two days later co-transfected with one of the plasmids above, renilla 
plasmid and pCMV Flag-YAP using GenJet transfection reagent. 36-48 hours after 
transfection cells were lysed using lysis buffer (91.5 mM K2HPO4, 8.5 mM KH2PO4, 
0.2% Triton-X-100 [v/v], 1 mM DTT, 1 mM PMSF) and lysates were transferred into a 
white 96-well plate (Corning). Luminescence was induced by using the Dual-Glo® 
luciferase assay system (Promega) and was detected by a Biotek HT plate reader. 
Luciferase activity was normalised to renilla signal. 
 
Table 7: Primers used for cloning plasmids carrying promoter regions 
Target Sequence 
CAVIN1 (-1250) TAAGGTACCCCCCGGGTTCAAGTGATT 
CAVIN1 (+150) TTATGACGCGTGGAAGGGAGGAGAGCTAGC 
CAVEOLIN1 (-1800) TTATGACGCGTCTGCAGTGACCTATGAATGCA 
CAVEOLIN1 (-500) TTATGACGCGTCTTATTTCGAAGCGTTTGGG 




3.3.5 Flow cytometry Analysis 
Intracellular labelling of proteins and analysis of their expression on a single cell basis 
was performed by flow cytometry assay. BOECs and HEK 293A cells were trypsinised 
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and resuspended in medium, centrifuged, washed once with 1x PBS (without calcium 
and magnesium), centrifuged again and washed a second time with FACS buffer 
(0.5% BSA, 0.2 mM EDTA in PBS). The cell number was determined and 1.5x105 
cells/well were seeded into a round-bottom 96-well plate (Corning). The plate was 
centrifuged at 300 g for 5 minutes and the FACS buffer was discarded. Cells were 
resuspended in 100 µl Zombie aqua (#423101, BioLegend) solution (1:100 in 1x PBS) 
and incubated for 10 minutes in the dark. The plate was centrifuged, as before, and 
cells were washed once with 150 µl PBS per well. PBS was discarded and cells were 
resuspended in 100 µl of Fix/Perm solution (1:3 concentrate [#00-5123-43] in diluent 
[#00-5223-56], Invitrogen). The plate was wrapped in tin foil and cells were incubated 
overnight at 4°C. The next day, the plate was centrifuged, and cells were washed 
twice with 1x permeabilisation buffer (from 10x [#00-8333-56] diluted in PBS, 
Invitrogen). Subsequently, cells were incubated in 100 µl/well blocking solution (5% 
goat serum [sigma] in 1x permeabilisation buffer) for 10 minutes in the dark at room 
temperature. Without removing the blocking solution, 50 µl of primary antibody 
solution, at a final dilution of 1:100 (in permeabilisation buffer), were added per well. 
Antibodies against CAV1 (#BD610060), VE-Cadherin (#D87F2) and PECAM1 
(#SC1506) were used (see also Table 8). After 30 minutes of incubation in the dark, 
the plate was centrifuged, and cells were washed twice with permeabilisation buffer. 
100 µl/well secondary antibody solution were added (anti-mouse AF647 [#1030-31, 
SouthernBiotech] or anti-rabbit AF647 [#Z25308, Invitrogen] diluted 1:400 in 
permeabilisation buffer). In the dark, the cells were incubated for 30 minutes with 
secondary antibodies. Afterwards the cells were washed two more times in 
permeabilisation buffer and finally resuspended in 100 µl FACS buffer. For analysis 
the cells were transferred into FACS tubes and resuspended in additional 150 µl of 
FACS buffer. The flow cytometry analysis was performed on the 5 LSRFortessa (BD 
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Biosciences) and with the assistance of Shonna Johnston (UoE). The gating was as 
follows; side scatter area vs forward scatter area (SSC-A/FSC-A) to identify cells. 
forward scatter height vs area (FCS-H/FCS-A) to sort for singlets. To identify live cells 
(alive at the time of fixation), Zombie aqua positive cells were detected. Finally, cells 
labelled with the AF647 fluorophore were detected. As the primary antibodies were 
not conjugated with a fluorophore, secondary antibodies had to be used. In order to 
test for background signal by unspecific binding of secondary antibodies, cells were 
incubated with secondary antibodies only. Furthermore, to be able to detect 
autofluorescence in the range of the secondary antibodies used, one well per cell line 
remained unlabelled with antibodies and only the signal of Zombie aqua was detected. 
 
3.4 Microbiological Techniques 
3.4.1 Generation of Competent Dh5α E.coli 
Chemically competent E.coli bacteria (initial stock kindly provided by Sonja Vermeren, 
UoE) were generated following a method using rubidium chloride. An overnight 
culture of E.coli in LB (Luria Bertani) medium (1% tryptone, 0.5% yeast extract, 1% 
NaCl, pH7.5) was diluted 1:100 in 5 ml YT++ medium (0.8% tryptone, 0.5% yeast 
extract, 0.5% NaCl 3.5 mM NaOH) and incubated for 3.5 hours at 37°C in an orbital 
shaker. This culture was then used to inoculate 100 ml of pre-warmed YT++ medium, 
which was cultured until the bacteria suspension reached an OD600 of 0.45-0.55. The 
bacterial suspension was then divided into pre-chilled 50 ml Falcon tubes in 50 ml 
aliquots, the suspension was left on ice for 5 min and subsequently pelleted at 1700 
g for 15 min at 4°C. On ice, the pellets were resuspended each in 10 ml of ice cold 
TFB1 buffer (30 mM potassium acetate, 50 mM MnCl2, 100 ml RbCl2, 10 mM CaCl2, 
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15% glycerol, pH5.8, sterile filtered), which was followed by a 10 min incubation on 
ice. The suspension was then centrifuged as above, and the supernatant was 
discarded. The bacteria pellets were resuspended in each 2 ml of ice-cold TFB2 (10 
mM Na-MOPS, 75 mM CaCl2, 10 mM RbCl2, 15% glycerol, pH7, sterile filtered). The 
competent bacteria suspension was aliquoted as 100 µl portions into pre-cooled (on 
ice) 1.5 ml tubes and snap frozen in an ethanol-dry ice bath and stored at -80°C.  
 
3.4.2 Transformation of Competent Dh5α E.coli, DNA 
Propagation and Isolation 
Transformation of competent Dh5α E.coli bacteria was carried out by heat shock, 
whereupon bacteria were seeded onto selective agar. In detail, after thawing on ice, 
bacteria were incubated with plasmids for 30 minutes on ice and heat-shocked at 
42°C for 45 seconds, followed by a 2-minute incubation on ice. Bacteria were 
resuspended in 900 µl LB medium (10 mg/ml bacto-tryptone, 5 mg/ml yeast extract, 
10 mg/ml NaCl, pH7.5) and incubated at 37°C in a bacteria shaker. After one hour, 
cells were pelleted, resuspended in 50-100 µl of LB, while 10-50 µl of this solution 
was plated onto LB agar with selection (e.g. 100 μg/mL carbenicillin) and incubated 
at 37°C. The following day single clones were picked and used to inoculate LB 
medium (with appropriate selection) and propagated by overnight incubation in an 
orbital shaker at 37°C. The next day plasmids were harvested using the EZNA KIT 
PLASMID MINI I (Q-SPIN) kit (Omega Biotek). Glycerol stocks of bacteria were 
generated by resuspending fresh bacteria suspension 1:1 in sterile 50% glycerol and 
stored at -80°C. 
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3.5 Zebrafish Assays 
3.5.1 Zebrafish Husbandry and Mutants 
Danio rerio Zebrafish (ZDR strain) were kept by Dr Isabel Ribeiro Bravo at the 
Bioresearch & Veterinary Services Aquatics facility (UoE) or by the Link lab (MCW). 
The following lines were used by the Link lab to generate yap/taz (wwtr1) double 
homozygous mutants; yap1mw48 (c. 158-161del), this allele has a 4 bp deletion within 
exon1 [66] and wwtr1mw49 (c. 156-160del), this allele has a 5 bp deletion within exon1 
[66]. In addition, cav1/cav3 double homozygous mutants were obtained by the Link 
lab and have been described elsewhere [202]. I performed qPCR on cDNA obtained 
from yap/taz KO zebrafish (see 3.3.2) and whole zebrafish immunohistochemistry on 
cav1/cav3 KO fish (see 3.6.2). For details on the methodology of the remaining 
experiments with zebrafish models please refer to Rausch et al. [195]. 
 
3.5.2 Zebrafish Yap Localisation Reporter 
Yap localisation was assessed specifically in zebrafish epidermal cells which express 
a GFP-labelled Tead-binding deficient mutant version of Yap (GFP-YapS54A) as well 
as a nuclear marker (H2A-mCherry). Experiments with these reporter zebrafish were 
kindly performed by the Link lab (MCW) and analysed by Carsten G. Hansen (UoE). 
For details please refer to Rausch et al. [195]. 
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3.6 Microscopy 
3.6.1 Immunocytochemistry (Immunofluorescence) 
The preparation of cells for immunofluorescence (IF) staining is explained in great 
detail in Rausch and Hansen [203]. The antibodies used for this method are listed in 
Table 8. Image acquisition was performed by a Zeiss 780 inverted confocal laser 
scanning microscope (CLSM) utilising a Plan-Apochromat 63x/1.4 Oil DIC M27 
objective. Microscope settings were kept constant between samples for direct 
comparison. Image acquisition and quantification were generously carried out by 
Carsten G. Hansen (UoE) and is explained in detail in Rausch et al. [195]. Quantified 
were five to 15 cells of each population in eight to 15 images per condition. The 
experiments were carried out 2-3 times. 
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Table 8: Antibodies used for immunocytochemistry and flow cytometry 
Target Dilution Source Identifier 
Anti-YAP/TAZ 1:100 Santa Cruz Biotechnology Cat# sc-101199 
Anti-CAV1 1:500 BD Biosciences Cat# BD610060 
Anti-CAV2 1:100 BD Biosciences Cat# BD610684 
Anti-YAP 1:300 Abcam Cat# ab52771 
Anti-CAVIN1 1:300 Abcam Cat# ab48824 
Anti-GFP 1:300 Abcam Cat# ab6556 
Anti-CAV1 1:300 
Jørgen Vinten, University of 
Copenhagen 
See [204] 
Anti-Myc 1:500 Cell Signaling Technology Cat# 2276 
Anti-TEAD1 1:100 BD Biosciences Cat# 610923 
Anti-FLAG 1:200 Cell Signaling Technology Cat# 2368 
Anti-PECAM1 1:400 Santa Cruz Biotechnology Cat# SC1506 
Anti-VE-Cadherin 1:400 Cell Signaling Technology Cat# D87F2 
Anti-Rabbit IgG 2°AB, 
Alexa Fluor 488 
1:400 Thermo Fisher Scientific Cat# A-11008 
Anti-Rabbit IgG 2°AB, 
Alexa Fluor 594 
1:400 Thermo Fisher Scientific Cat# A-11037 
Anti-Mouse IgG 2°AB, 
Alexa Fluor 594 
1:400 Thermo Fisher Scientific Cat# A-11032 
Anti-Mouse IgG 2°AB, 
Alexa Fluor 488 
1:400 Thermo Fisher Scientific Cat# A-11029 
Anti-Rabbit IgG 2°AB, 
Alexa Fluor 633 
1:400 Thermo Fisher Scientific Cat# A-21071 
Anti-Mouse IgG 2°AB, 
Alexa Fluor 647 
1:400 SouthernBiotech Cat# 1030-31 
Anti-Rabbit IgG 2°AB, 
Alexa Fluor 647 
1:400 Invitrogen Cat# Z25308 
2°AB: Secondary antibody 
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3.6.2 Whole Zebrafish Immunohistochemistry 
For whole mount immunohistochemistry fixed zebrafish embryos were washed in 
PBST and stored in 100% methanol at -20°C overnight. This was followed by 
rehydration in solutions of incrementally increased PBST concentration (25%, 50%, 
75% PBST in methanol) and a final wash in PBST. Subsequently, embryos were 
incubated in blocking buffer (10% goat serum, 0.2% BSA in PBST) for several hours 
at room temperature. For labelling of YAP, embryos were left in blocking solution with 
anti-YAP antibody (#13584-1-AP, Proteintech) at 4°C overnight. After rigorous 
washing in PBST, embryos were incubated in blocking solution containing secondary 
antibody (Alexa Fluor 633, A21071, Thermofisher), which was followed by another 
extensive washing procedure. Nuclei were labelled by Hoechst 3342 (Thermofisher). 
Finally, embryos were dehydrated in glycerol solutions (30%, 50%, 80% 
glycerol/PBS) and stored in antifadent (AF1, Citifluor). Labelled zebrafish embryos 
were mounted in antifadent onto glass slides and microscopic images were taken 
using the Leica SP8 CLSM utilising a HC PL APO 40x oil CS2 objective. The nuclear 
to cytoplasmic YAP ratio in individual cells was kindly determined by Carsten G. 
Hansen (UoE), for details please see Rausch et al. [195]. 
 
3.6.3 Transmission Electron Microscopy (EM) 
Zebrafish embryos were collected at the 12-somite stage and prepared as previously 
described [200]. Four embryos were analysed for each genotype. Sample preparation 
and imaging was generously performed by the Link lab (MCW). Quantification was 
kindly conducted in a genotype-blinded manner by Carsten G. Hansen (UoE). For 
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details on sample preparation, imaging and quantification please refer to Rausch et 
al. [195]. 
 
3.6.4 Shear Stress Studies 
Cells were cultured under laminar flow using the Kirkstall Quasi Vivo® QV500 system 
with a Parker (PF22X0103) peristaltic pump. HEK 293A cells were seeded onto 
ThermanoxTM 13 mm coverslips (#174950, ThermoFisher), or (for IF) poly-D-lysine 
coated glass coverslips and grown to confluency in complete DMEM containing 10% 
FBS. The coverslips were transferred into the QV500 system and cells were cultured 
in DMEM (with supplements as described above) containing 0.1% FBS and a constant 
flux of 4.7 and 2.1x10-5 Dyn/cm2, respectively. After 18 hours cells were harvested 
and analysed by RT-qPCR, Western blotting or IF. 
 
3.6.5 Statistics and Data Presentation 
Data is represented with probability (p) values used by “*” p<0.05, “**” p<0.01 and 
“***” p<0.001. All data originated from at least three independent biological replicates 
if not directly stated otherwise. Data was analysed using Fiji (ImageJ), Excel 
(Microsoft) and Prism (GraphPad) software. All statistical analysis and graphs were 
generated using Prism software. All IF based scatter plots were tested and analysed 
by unpaired (Student’s) t-test, whereas all other data was analysed using Mann-
Whitney, if not specifically mentioned in the figure legends. Data are represented as 
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4. Results 
4.1 YAP and TAZ Drive Caveolar Protein 
Expression 
YAP and TAZ regulate the expression of a large variety of genes. Here, the 
importance of YAP/TAZ for the expression of two main caveolar components was 
investigated. YAP/TAZ as well as LATS1/2 HEK 293A double KO cell lines, were 
previously described [196, 197]. These genome edited cell lines were central to 
determine the dependence of caveolar gene and protein levels on YAP/TAZ activity 
and analysed by immunofluorescence, RT-qPCR and Western blotting. Furthermore, 
the established YAP/TAZ and LATS1/2 double KO cell lines allowed for the 
verification of antibodies against YAP/TAZ and YAP used for this study (Figure 8) 
[197, 203]. 
 
Figure 8: Validation of antibody specificity. 
Confocal laser scanning microscopy (CLSM) images of discrete HEK 293A cell 
cultures of WT and YAP/TAZ#1 double KO cells, respectively. Cells were f ixed 
and labelled for YAP/TAZ (red), YAP (green) and counterstained with DAPI 
(blue); Antibodies against YAP/TAZ (Santa Cruz, sc101199) and YAP (Abcam, 
ab52771). The single channel images visualise the specif icity of the antibodies. 
Scale bar = 15µm. 
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A strong reduction of both CAV1 or CAVIN1 signals became evident in two 
independent YAP/TAZ KO cell lines (#1 and #2) compared to WT cells (Figure 9A,B). 
On the other hand, LATS1/2 KO cells, compared to WT cells, showed increased CAV1 
and CAVIN1 signal (Figure 9A-C). LATS1/2 are negative regulators of YAP/TAZ [13]. 
LATS1/2 KO causes YAP/TAZ hyperactivity, as indicated by the nuclear accumulation 
of YAP/TAZ signal (Figure 9C,D). The quantification of relative CAV1 and CAVIN1 
signal in the YAP/TAZ#1 KO compared to WT cells showed a significant reduction of 
the two central caveolar components, while this signal was increased in LATS1/2 KO 
cells (Figure 9E,F). 
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Figure 9: CAV1 and CAVIN1 depend on YAP/TAZ expression. 
A-C: CLSM images of discrete HEK 293A cell cultures of WT and two 
independent YAP/TAZ KO cell lines (A and B) and LATS1/2 KO cells (C). Cells 
were fixed and labelled for YAP/TAZ (red) and ei ther CAV1 or CAVIN1 (green) 
and counterstained with DAPI (blue). Samples were all imaged in parallel and 
with similar settings to allow for direct comparison between cell l ines. Scale bar 
= 15µm. D:  Quantif ication of nuclear to cytoplasmic signal of YAP/TAZ in WT 
cells (as in A and B) and LATS1/2 KO cells (as in C). E:  Quantif ication of relative 
CAV1 signal in YAP/TAZ KO, WT and LATS1/2 KO cells. F: Quantif ication of 
relative CAVIN1 signal in YAP/TAZ KO, WT and LATS1/2 KO cells. For D -F: Each 
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Along with CAV1 and CAVIN1, YAP/TAZ-deficient cells, unlike LATS1/2 KO cells, had 
a strong reduction of CAV2 expression (Figure 10). This indicates that the levels of 
these important caveolar proteins are positively correlated with YAP/TAZ activity. 
 
 
Figure 10: CAV2 depends on YAP/TAZ expression. 
CLSM images of discrete HEK 293A cell cultures of WT, YAP/TAZ#1 KO and 
LATS1/2 KO cells. Cells were fixed and labelled for CAV2 (red), CAV1 (green) 
and counterstained with DAPI (blue). Samples were all imaged in parallel and 




To determine whether YAP/TAZ-dependent caveolar protein expression is a cell-
intrinsic effect, and not solely due to paracrine interactions, mixed (WT and KO) cell 
populations were analysed by immunofluorescence assays. The specificity of the 
antibodies used (Figure 8), allowed for directly comparison of CAV1 and CAVIN1 
expression between WT and YAP/TAZ KO cells in a mixed culture (Figure 11). As in 
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the discrete cultures, CAV1, CAVIN1 as well as CAV2 protein expression were 
drastically reduced in YAP/TAZ-deficient cells both qualitatively (Figure 11A-C) and 
quantitatively (Figure 11D,E). An effect which was reproduced in a second YAP/TAZ 
KO cell line (#2) (Figure 11F,G) and indicates a cell-intrinsic dependence of caveolar 
proteins on YAP and TAZ. 
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Figure 11: YAP/TAZ regulate CAV1 and CAVIN1 expression cell-intrinsically. 
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A-C: CLSM images of mixed cultures of f ixed HEK 293A WT and YAP/TAZ#1 KO 
cells labelled for YAP/TAZ (red in A and B), CAV1 (green in A), CAVIN1 (green 
in B) or YAP (green in C) and CAV2 (red in C) and counterstained with DAPI 
(blue). Arrows indicate KO cells.  On the r ight, zoom-out image of cell culture, 
highlighting the selected zoom-in by the red dashed-line box. Scale bars = 15µm. 
D: Quantif ication of relative CAV1 signal in YAP/TAZ KO and WT cells (as in A). 
E:  Quantif ication of relative CAVIN1 signal in YAP/TAZ KO and WT cells (as in 
B). For D and E: Each dot represents one cell . n ≥  120. T-test, mean ± SEM. F 
and G:  Images as in A and B but of WT and YAP/TAZ#2 KO cells.  
 
 
In addition, exogenous plasmid-based re-expressed CAV1 and CAVIN1 in YAP/TAZ 
KO cells co-localised within, or close to, plasma membrane domains (Figure 12A). 
This localisation is comparable to the localisation of endogenous CAV1 and CAVIN1 
in WT cells (Figure 12B). These data indicate that YAP and TAZ are required for the 
expression of the essential caveolar proteins CAV1 and CAVIN1, but YAP and TAZ 
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Figure 12: Exogenous expression of CAV1 and CAVIN1 form caveolae-like plasma 
membrane domains in YAP/TAZ KO. 
A:  Expression of CAVIN1-mCherry (red) and CAV1-GFP (green) in HEK 293A 
YAP/TAZ KO cells. Cells were fixed and processed for CLSM im aging. Note the 
co-localisation of CAV1 and CAVIN1 in plasma membrane domains. Red boxes 
indicate inserts shown below. Arrows: untransfected cells. Scale bar = 20 µm. B:  
CLSM images of HEK 293A WT cells  f ixed and processed for 
immunofluorescence, labelled for endogenous CAVIN1 (green), CAV1 (red) and 
counterstained for DAPI (blue). Note, CAV1 and CAVIN1 co -localise as in A. Red 
boxes indicate inserts shown below. Scale bar = 20 µm.  
 
 
The correlation between YAP/TAZ and the expression of caveolar components 
was mirrored by total protein levels. Western blotting analysis revealed a 
dramatic reduction of CAV1, CAV2 and CAVIN1 (as well as CAVIN3) protein 
levels in both YAP/TAZ KO (#1 and #2) cell lines (Figure 13A,B). In addition, it 
is worth noting that the reduction of LATS2 protein levels in YAP/TAZ KO cells 
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(Figure 13A,B) goes along with reports in the literature on the positive regulation 
of LATS2 transcription by YAP/TAZ [196]. On the other hand, in the LATS1/2 
KO cell lines YAP was hypo-phosphorylated, as seen by the downshift of the 
YAP signal in the PhosTag gel-based Western blot (Figure 13C). Consequently, 
in LATS1/2 KO cells YAP (and TAZ) were active and the expression of the 
caveolar components was increased (Figure 13A-C).  
 
Figure 13: YAP/TAZ activity is important for expression of caveolar proteins. 
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Western blot analysis of cell lysates from YAP/TAZ (Y/T) KO, WT and LATS1/2 
(L1/L2) KO cells. GAPDH and HSP90 served as loading controls.  Depending on 
the protein tested n ≥ 3.  A: Western blots of YAP/TAZ#1 KO, WT and LATS1/2#1 
KO. B: Western blots of YAP/TAZ#2 KO, WT and LATS1/2#2 KO. C: Western 
blot based on a PhosTag SDS-gel blotted for YAP protein of lysates as in A.  
 
 
Re-introduction of LATS1 into the LATS1/2 KO cells reversed this effect, while a 
kinase-dead version (K/R) did not (Figure 14A). Only LATS1/2 KO cells expressing 
the fully functional version of LATS1, but not the K/R mutant revealed an increase of 
phosphorylated YAP (Figure 14B). On total protein levels, cells expressing the K/R 
mutant behaved similar to the KO, while the LATS1 WT expressing cells had 
increased levels of the YAP/TAZ target CYR61 as well as CAV1 and CAVIN1 (Figure 
14A). These data demonstrate the importance of LATS1/2-dependent 












Figure 14: Active LATS1 inhibits caveolar 
protein expression. 
A:  Western blot of HEK 293A LATS1/2 KO 
cells stably expressing vector control ( -), 
LATS1 WT or a mutant LATS1 kinase-dead 
(K/R). B: Western blot based on a PhosTag 
SDS-gel probing for YAP protein of lysates 
as in A. Depending on the protein tested n 
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4.2 Expression of Caveolar Components 
Depends Transcriptionally on YAP/TAZ 
Activity 
Since YAP and TAZ are transcriptional co-activators and the expression of central 
caveolar proteins depends on their activity (as seen in 4.1), I sought out to determine 
whether YAP/TAZ activity directly regulates caveolar gene expression. RT-qPCR 
analyses revealed a significant decrease of not only the well-known YAP/TAZ target 
genes CYR61 and CTGF but of CAV1 and CAVIN1 mRNA in both YAP/TAZ KO cell 
lines (Figure 15A-C). In the LATS1/2 KO cells, with hyperactive YAP/TAZ, an increase 
in CYR61, CTGF and CAVIN1 mRNA was apparent (Figure 15A,B). Re-expressing 
WT but not the kinase-dead K/R version of LATS1 in the LATS1/2 KO cells led, as on 
protein levels (Figure 14A), to a decrease of both YAP/TAZ target genes as well as 
CAVIN1 (Figure 15D). In addition, exogenous expression of hyperactive YAP (5SA 
mutant) increased CAV1 and CAVIN1 expression (Figure 15E). Consequently, 
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Figure 15: Active YAP/TAZ induce transcription of caveolar gene. 
A:  RT-qPCR analysis of expression of established YAP/TAZ target genes in HEK 
293A YAP/TAZ#1 KO and LATS1/2 KO relative to WT cells. B: RT-qPCR analysis 
of expression of essential caveolar genes in HEK 293A YAP/TAZ#1 KO and 
LATS1/2 KO relative to WT cells. C:  RT-qPCR analysis as in A and B of HEK 
293A YAP/TAZ#2 KO cells.  n = 2 D: RT-qPCR analysis of expression of 
established YAP/TAZ target genes and essential caveolar genes in HEK 293A 
LATS1/2 KO stably expressing LATS1 WT or a kinase-dead (K/R) LATS1 relative 
to LATS1/2 KO cells. n ≥ 2 E:  RT-qPCR analysis of expression of essential 
caveolar genes in HEK 293A cells stably expressing the constitutive active S5A 
version of YAP relative to cells stably expressing YAP WT.  n ≥ 3.  Mann-Whitney 
test, mean ± SD. 
 
 
4.2.1 YAP/TAZ-TEAD Interaction is Important for CAV1 
and CAVIN1 Expression 
YAP and TAZ are co-transcriptional activators, however as they do not contain any 
DNA binding domains, they are incapable of inducing gene transcription by 
themselves. They bind to transcription factors, e.g. TEAD1-4, and as a complex locate 
to distal enhancer and promoter regions of Hippo pathway regulated genes [15, 18, 
25, 30, 205]. The expression of caveolar components (CAV1, CAV2, CAVIN1, 
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CAVIN3) depends on YAP/TAZ expression and activity (see above), however whether 
the central caveolar genes CAV1 and CAVIN1 are transcriptionally regulated via 
TEAD was unclear. Therefore, I analysed the expression of CAV1 and CAVIN1 in 
cells deficient for TEADs as well as cells where the interaction between YAP/TAZ and 
TEAD was inhibited.  
A drug, which inhibits the YAP-TEAD interaction is verteporfin [206]. Clinically, 
verteporfin is used as a photosensitiser in photodynamic therapy [207]. Verteporfin 
binds YAP leading to a conformational change, which inhibits the ability of YAP to 
bind TEADs [206]. Verteporfin further appears to affect the Hippo pathway by 
increasing the levels of 14-3-3, which induces YAP/TAZ cytoplasmic retention [208, 
209]. After treating cells with verteporfin there was a significant reduction of both 
CYR61 and CTGF as well as CAV1 and CAVIN1 mRNA levels relative to untreated 
cells (Figure 16). 
 
Figure 16: YAP-TEAD interaction important for caveolar 
gene expression. 
Verteporfin treated HEK 293A WT cells analysed by 
RT-qPCR for expression of YAP/TAZ target genes and 
central caveolar components relative to cells not 
treated with verteporfin. n ≥ 4. Mann-Whitney test, 
mean ± SD. 
 
 
Importantly, the specificity of verteporfin has recently come under scrutiny, when, e.g. 
no effect was detected in melanoma model [210]. Therefore, in order to not only rely 
on drug treatments, a genetic approach was adopted to analyse the TEAD-
dependency further. YAP binds to TEAD via forming a hydrogen bond at its serine 94 
[15, 25]. In a complementary approach a WT or a TEAD binding-deficient version of 
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YAP (S94A), mutated at serine residue 94, or the equivalent TAZ (S51A), mutated at 
its TEAD interaction site, serine residue 51, were stably (re-)introduced into YAP/TAZ 
KO HEK 293A cells. Analysing total protein levels, it was evident that there was an 
increase of CYR61, CAV1 and CAVIN1 protein in cells expressing YAP-WT compared 
to YAP/TAZ KO and YAP-S94A cells (Figure 17A). Immunofluorescent labelling of 
CAV1 and CAVIN1 revealed a rescue of their expression in cells transfected with the 
YAP-WT but not the TEAD binding-deficient YAP-S94A mutant. This YAP-TEAD 
binding rescue occurs in a cell-intrinsic manner as proven by a mixed cell culture 
approach (Figure 17B-G). The induction of CAV1 and CAVIN1 expression in YAP-WT 
expressing cells was significantly elevated compared to the YAP/TAZ KO and the 
YAP-S94A cells (Figure 17D,G). The increase of CAV1 and CAVIN1 expression was 
mirrored when comparing the above results with TAZ-WT re-expressing and TAZ-
S51A expressing cells (Figure 17H,I). Consequently, these results emphasise that the 
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Figure 17: YAP/TAZ-TEAD interaction important for caveolar protein expression. 
A:  Western blot analysis of lysates from HEK 293A YAP/TAZ#1 KO cells stably 
expressing vector control ( -), myc-tagged WT YAP or the TEAD-binding-deficient 
YAP S94A. l.e. = long exposure, s.e. = short exposure.  Depending on the protein 
tested n ≥ 2. B: Zoom-out image of cells as in C indicated by the red dashed-line 
box. C: CLSM images of mixed HEK 293A cultures YAP/TAZ#1 KO cells stabl y 
expressing vector control, myc-tagged YAP WT or YAP S94A. Cells were fixed 
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and labelled for myc (red), CAV1 (green) and counterstained with DAPI (blue). 
Arrows: Cells expressing the myc tag. D:  Quantif ication of relative CAV1 signal 
of cells as in C. E: Zoom-out image of cells as in F indicated by the red dashed-
line box. F: CLSM images of mixed HEK 293A cultures YAP/TAZ#1 KO cells 
stably expressing vector control, myc-tagged YAP WT or YAP S94A. Cells were 
fixed and labelled for myc (red), CAVIN1 (green) and counterstained with DAPI 
(blue). Arrows: Cells expressing the myc tag. G:  Quantif ication of relative 
CAVIN1 signal of cells as in F. H: CLSM images of mixed HEK 293A cultures 
YAP/TAZ#1 KO cells stably expressing vector control, f lag -tagged TAZ WT or 
the TEAD-binding-deficient TAZ S51A. Cells were fixed and labelled for f lag 
(green), CAV1 (red) and counterstained with DAPI (blue). Arrows: Cells 
expressing the flag tag. I:  Quantif ication of relative CAV1 signal of cells as in H. 
For C, F and H: Samples were all imaged in parallel and with similar setting to 
allow direct comparison. Scale bar = 15µm. For D, G and I: Each dot repr esents 
one cell. n ≥ 100. T-test, mean ± SEM. 
 
 
A significant increase of CAV1 and CAVIN1 mRNA was only detected in cells 
expressing the WT but not the TEAD-binding-deficient version of YAP or TAZ (Figure 
18A,B). This apparent dependence of CAV1 and CAVIN1 expression on the 
YAP/TAZ-TEAD interaction was an encouragement to analyse the role of TEADs in 
the expression of central caveolar components. 
 
Figure 18: YAP/TAZ-TEAD 
interaction essential for caveolar 
gene expression. 
A:  RT-qPCR analysis of 
expression central caveolar 
components in HEK 293A 
YAP/TAZ#1 KO cells stably 
expressing YAP S94A or WT, 
relative to KO cells. B: RT-
qPCR analysis as in A but of 
cells stably expressing TAZ 
S51A or WT, n ≥ 2. Mann-
Whitney test, mean ± SD. 
 
 
Therefore, shRNA-induced TEAD1/3/4 KD in HEK 293A cell lines (which naturally 
lack detectable TEAD2) were utilised to investigate changes in CAV1 and CAVIN1 
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expression (Figure 19). In discrete cultures of TEAD KD cells a reduction of CAV1 and 
CAVIN1 signal was detected by immunofluorescence assays compared to control 
cells (Figure 19A-C). Quantifying the relative signal of CAV1 and CAVIN1 revealed a 
significant reduction of the two essential caveolar components in TEAD-deficient cells 
(Figure 19D,E). Those results were mirrored in mixed cultures, indicating that it is not 
merely a paracrine effect but that the two essential caveolar components directly 
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Figure 19: Expression of CAV1 and CAVIN1 depends on TEAD. 
A and B: CLSM images of discrete cultures of HEK 293A shCon or shTEADs 
(TEAD1/3/4, cell l ine #1) treated cells. Cells were fixed and labelled for TEAD1 
(in A green, in B red), CAV1 (red in A) or CAVIN1 (green in B) and counterstained 
with DAPI (blue). Scale bars = 15 µm. C: Quantif ication of relative TEAD1 signal 
in control and TEADs KD cells as in A and C. D: Quantif ication of relative CAV1 
signal in control and TEADs KD cells as in A. E:  Quantif ication of relative CAVIN1 
signal in control and TEADs KD cells as in B. F and  G: CSLM images of mixed 
cultures of shCon and shTEAD#1 cells. Cells were fixed and labelled (in F) for 
CAV1 (red) and TEAD1 (green) or ( in G) CAVIN1 (green) and TEAD1 (red) and 
counterstained with DAPI (blue). Scale bars = 15 µm. H:  Quantif ication of relative 
CAV1 signal in control and TEADs KD cells as in F.  I: Quantif ication of relative 
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CAVIN1 signal in control and TEADs KD cells as in G. For C-E, H and I: Each 
dot represents one cell. n ≥  90. T-test, mean ± SEM. 
 
 
The caveolar TEAD dependence was further examined by total protein analysis 
(Figure 20A). Evidence that the regulation of the two essential caveolar genes CAV1 
and CAVIN1 are transcriptionally regulated by YAP/TAZ-TEAD was delivered by RT-
qPCR analysis of two independent TEAD-deficient cell lines. The results reveal a 
significant reduction of CAV1 and even more drastically CAVIN1 (Figure 20B,C). In 
conclusion, these data show that TEAD transcription factors and their interaction with 
YAP and TAZ is central for CAV1 and CAVIN1 expression. 
 
Figure 20: TEAD is 
required for expression 
of caveolar 
components. 
A:  Western blot 
analysis of cell 
lysates from HEK 
293A control or 
TEAD1/3/4 #1 KD cell 
l ines. HSP90 served 
as loading controls. 
B: RT-qPCR analysis 
of expression 
established YAP/TZA 
target genes and 
central caveolar 
components in HEK 
293A cells TEAD1/3/4 
#1 KD cells, relative to 
control cells. n ≥ 3. 
Mann-Whitney test, 
mean ± SD. C: RT-
qPCR analysis as in B 
but of a second 
TEAD1/3/4 (#2) KD 
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4.2.2 CAV1 and CAVIN1 are Direct Targets of YAP and 
TAZ-TEAD 
I performed luciferase promoter assays to determine whether the transcription factors 
TEAD localise at the promoter region of CAV1 and CAVIN1. Therefore, sequences of 
proximal genomic regions of either CAV1 or CAVIN1 were inserted into a plasmid 
upstream of the open reading frame of a luciferase gene. A long version of the CAV1 
promoter (-1800 to +200bp) as well as a sequence of the CAVIN1 promoter (-1250 to 
+150bp) harbour five and four predicted TEAD binding sites, respectively. While a 
short version of the CAV1 promoter region does not contain any TEAD recognition 
motifs (Figure 21A). When co-expressed with YAP, only cells with the plasmids 
containing genomic regions of CAV1 and CAVIN1 covering the TEAD binding sites 
showed increased luciferase activity. While the short CAV1 genomic region does not 
affect luciferase activity (Figure 21B). 
 
 
Figure 21: YAP drives CAVIN1 and CAV1 promoter activity. 
A:  Diagram of the CAVIN1 and CAV1 proximal promoter regions. Numbering in 
base pairs (bp) from transcription start site (TSS). ATG: Start codon. Red line: 
Representations of the regions contained in the luciferase reporter plasmid. 
Arrow heads: Predicted TEAD recognition motifs (including degenerate). The 
short fragment of the CAV1 promoter region (-500 to +200 bp) does not contain 
any predicted TEAD recognition motifs, while the long fragments of both CAV1 
(-1,800 to +200bp) and CAVIN1 (-1,250 to +150bp) do. B: HEK 293A YAP/TAZ#1 
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KO cells were transfected each with one of the plasmids with fragments of 
promoter regions as in A together with either a YAP or a vector control plasmid. 
Luciferase activity was measurable in cells transfected with the plasmids 
carrying promoter regions of CAV1 and CAVIN1 with TEAD binding motifs. n = 3. 
Mann-Whitney test, mean ± SD. 
 
 
To verify the results obtained above with the overexpressing approach, I next aimed 
to show YAP-TEAD binding to proximal promoter regions of CAV1 and CAVIN1 
endogenously in cells. Therefore, chromatin immunoprecipitation (ChIP) was 
performed. At first, the binding of TEAD1 to the promoter regions of CAV1 and 
CAVIN1, respectively, was verified. Performing the immunoprecipitation with a 
TEAD1 specific antibody, the subsequent qPCR analysis revealed enrichment of the 
proximal caveolar promoters bearing TEAD binding sites, but not of the in-gene 
negative controls (Figure 22A). Next, to assess whether YAP localises at the proximal 
promoters of CAV1 and CAVIN1, an immunoprecipitation was performed with an 
antibody against YAP. Again, the promoter regions of CAV1 and CAVIN1 were 
enriched (Figure 22B). Finally, to prove that the YAP-TEAD complex binds to the 
promoters of CAV1 and CAVIN1 the ChIP assay was performed with the TEAD KD 
cell line #1. Here the immunoprecipitation with the YAP specific antibody and 
subsequent qPCR analysis resulted in no enrichment of the promoter regions of CAV1 
and CAVIN1 (Figure 22C). In conclusion, the YAP-TEAD complex physically interacts 
with the proximal promoter regions of the two essential caveolar genes CAV1 and 
CAVIN1. In summary, these data show that YAP/TAZ activity and their interaction with 
TEAD regulate the expression of central caveolar components and that CAV1 and 








Figure 22: YAP-TEAD1 physically bind to the promoter regions of CAV1 and CAVIN1. 
A-C: qPCR analysis of chromatin immunoprecipitation (ChIP) in HEK 293A cells. 
The precipitated DNA was quantitated using primers specific for a promoter 
region or a control in-gene (Ing) region. Data are means ± SD of tr iplicates from 
a representative experiment. A: Immunoprecipitation was performed with an 
antibody against TEAD1 in HEK 293A WT cells. B: Immunoprecipitation was 
performed with an antibody against YAP in HEK 293A control (shCon) cells. C:  
Immunoprecipitation was performed with an antibody against YAP in HEK 293A 
TEAD1/3/4 KD (#1) cells . 
 
 
4.2.3 YAP/TAZ Activity-dependent Expression of 
Caveolar Components is a Widespread 
Phenomenon 
The conclusion that caveolar gene expression depends on YAP/TAZ activity, was 
further supported by a cancer cell line which, is known to have a functional Hippo 
pathway [87] and shows high relative expression and correlation between CYR61 and 
CAV1 as well as of CAVIN1 [195]. U2OS is a human osteosarcoma cell line and was 
used to further establish the CAV1 and CAVIN1 dependency on YAP/TAZ-TEAD. 
Different KO and KD U2OS cell lines were therefore generated. I aimed to generate 
CRISPR/Cas9-mediated YAP/TAZ double KO cell lines based on U2OS. However, 
even after multiple repeated attempts, with verified active guide sequences, I was not 
able to obtain a viable YAP/TAZ double KO U2OS cell line. This is an indicator of the 
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central role of YAP and TAZ for those osteosarcoma derived cells. The KO of YAP or 
TAZ in combination with the KD of TAZ or YAP showed a strong reduction of CYR61 
and, importantly, of both CAV1 and CAVIN1 expression in U2OS cells (Figure 23A-C). 
 
Figure 23: YAP/TAZ dictate caveolar protein expression in U2OS cells. 
Western blot analysis of cell lysates from U2OS cells. HSP90 served as loading 
controls. Depending on the protein tested n ≥ 2. A:  Comparison of protein levels 
in U2OS WT, YAP KO and TAZ KO cells.  B: YAP KO cells with control (shCon) 
or TAZ KD. C: TAZ KO cells with control or YAP (shYAP) KD.  
 
 
4.2.4 The Role of the Upstream Hippo Pathway and NF2 
for Caveolae 
Above, I verified the central roles of not only YAP/TAZ, but also other Hippo pathway 
components, e.g. LATS1/2 and TEADs, for the expression of CAV1 and CAVIN1 (see 
4.1). Another important Hippo pathway regulator is Neurofibromatosis type 2 (NF2, 
also known as merlin) [211-215]. NF2 is an upstream activator of the kinase cascade 
and, consequently, an inhibitor of YAP/TAZ and the most commonly mutated Hippo 
pathway tumour suppressor [2, 21]. NF2 KO in U2OS cells resulted in nuclear 
accumulation of YAP/TAZ (Figure 24A,B). The increased nuclear localisation of YAP 
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goes along with its hypo-phosphorylation profile seen by PhosTag-analysis, an effect, 
which is reversed upon NF2 re-expression (Figure 24C). The activation of YAP (and 
TAZ) was accompanied by increased CAV1 and CAVIN1 protein levels (Figure 24D). 
Interestingly, the induction of caveolar gene expression both on protein and mRNA 
levels was blunted by re-introduction of NF2 (Figure 24E,F). Thus, the re-expression 
of NF2 indicates that CAV1 and CAVIN1 expression is inhibited by NF2. In order to 
assess the role of downstream Hippo pathway components in the context of NF2 
deficiency, KD of YAP, TAZ and TEADs, respectively, was induced in NF2 KO cells. 
Deficiency of TEADs and TAZ in particular led to a reduction of CAV1 in U2OS WT 
cells (Figure 24G). Correspondingly, the KD of TEADs and TAZ in NF2 KO cells had 
a strong negative effect on CAV1 expression, which grossly cancelled out the CAV1 
induction due to NF2 KO U2OS cells (Figure 24G). Importantly, TEAD deficiency led 
to reduced CYR61, CAV1 and CAVIN1 mRNA expression both in WT and NF2 KO 
cells (Figure 24H,I). Consequently, as in HEK 293A cells (Figure 19), the expression 
of CAV1 and CAVIN1 in U2OS cells is TEAD-dependent. 
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Figure 24: NF2 supresses expression of caveolar components. 
A:  CLSM images of discrete U2OS cell cultures of WT and NF2 KO lines. Cells 
were fixed and labelled for YAP/TAZ (green) and counterstained with DAPI 
(blue). Samples were imaged in parallel and with similar settings to allow direct 
comparison between cell l ines. Scale bar = 20µm. B: Quantif ication of nuclear to 
cytoplasmic signal of YAP/TAZ (Y/T) in WT and NF2 KO cells (as in A). Each dot 
represents one cell, n ≥ 80. Mean ± SEM. C:  Western blot based on a PhosTag 
SDS-gel probing for YAP protein of cell lysates  of U2OS WT and NF2 KO cells 
re-expressing either a vector (control) or NF2. D:  Western blot analysis of cell  
lysates from U2OS NF2 KO and WT cells. E:  Western blot analysis of cell lysates 
from lysates as in C. F:  RT-qPCR analysis of U2OS NF2 KO cells re-expressing 
NF2, relative to NF2 KO. n = 2. Mean ± SD. G: Western blot analysis of cell 
lysates from U2OS WT and NF2 KO cells with shRNA-induced KD of genes 
depicted. D, E and G: GAPDH served as loading control. H:  RT-qPCR analysis 
in U2OS NF2 KO cells with TEAD1/3/4 #1 KD, relative to NF2 KO. n ≥ 2. Mean ± 
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SD. I:  RT-qPCR analysis in U2OS WT cells with TEAD1/3/4 #1 KD, relative to 
WT. n ≥ 2. Mann-Whitney test, mean ± SD. 
 
 
4.2.5 YAP/TAZ Activity Governs Expression of Caveolar 
Components also in vivo 
Combined KO of YAP and TAZ in both mice and zebrafish is embryonic lethal [59, 66, 
216]. In vitro YAP/TAZ-deficiency has a strong impact on caveolar gene expression 
as shown above. To examine if the dependence of caveolae on YAP/TAZ is also 
present across species and in vivo we examined zebrafish embryos. 12-somite-stage 
Yap/Taz KO fish were compared to age- and background-matched WT embryos. 
Samples for electron microscopy were prepared (by the Link Lab) and Carsten G. 
Hansen quantified the abundance of caveolae structures in the fish epidermis. 
Yap/Taz-deficient epidermal cells have strongly decreased caveolae numbers 
compared to WT fish (Figure 25A,B). To determine if the reduction of caveolar 
structures was a result of diminished caveolar gene expression, I performed qPCR 
analysis on cDNA samples of those fish embryos (provided by the Link Lab). Relative 
to the WT, Yap/Taz KO embryos showed a downregulation of the well-known Yap/Taz 
target genes, cyr61 and ctgf as well as cav1 and cavin1 (Figure 25C). In conclusion, 
upstream regulators and downstream components of the Hippo pathway are key 
mediators for caveolar gene expression across cell lines and YAP/TAZ-TEAD harbour 








Figure 25: Reduction of caveolae in yap/taz KO zebrafish. 
A:  Electron microscopic micrographs from epidermis cells from WT and yap/taz  
KO zebrafish embryos. Arrows: Examples of caveolae at the plasma membrane. 
Scale bar = 500 nm. Samples and images obtained by the Link lab (MCW). 
Quantif ication performed by Carsten G. Hansen (UoE).  B: Quantif ication of 
caveolae abundance per millimetre in images as in A. n = 4. Mean ± SEM. 
Quantif ication performed by Carsten G. Hansen (UoE).  C:  RT-qPCR analysis to 
f ive zebrafish embryos of each genotype.  n = 3. Mann-Whitney test, mean ± SD. 
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4.3 CAV1 and CAVIN1 Inhibit YAP/TAZ Activity 
The understanding of the regulation of the Hippo pathway and YAP/TAZ activity is still 
incomplete. However, it is well-established that Hippo pathway components and some 
of its effectors are part of feedback responses [2, 196]. Hence, I sought to determine 
whether the central caveolar components CAV1 and CAVIN1 regulate YAP/TAZ 
activity.  
 
4.3.1 CAV1 and CAVIN1 deficiency Induces YAP/TAZ 
Activity in vitro 
Initial experiments with CAV1 U2OS KD cells revealed an induction of YAP/TAZ 
activity, indicated by the decrease of the inhibitory S127-phosphorylation of YAP, and 
an increase in CYR61 and CTGF protein levels (Figure 26A). In addition, these data 
confirmed the dependence of protein stability of CAVIN1 and CAVIN2 on CAV1 
expression [102] (Figure 26A-D). Employing the mixed cell culture approach allows 
the investigation of whether YAP/TAZ hyperactivation was a result of paracrine 
effects. Immunofluorescence labelling of YAP/TAZ and CAV1 revealed an increased 
nuclear localisation of YAP/TAZ in CAV1 KD compared to control cells (Figure 26E,F). 
These results are in agreement with increased CYR61 protein expression in three 
independent CAV1 KD cell lines compared to control cells (Figure 26G,H). In order to 
determine whether the increase in CYR61 and CTGF levels are due to induction of 
YAP/TAZ-TEAD transcriptional activity, mRNA levels in shCAV1 and shCAVIN1 cells 
were analysed. Both the CAV1 and the CAVIN1 deficiency led to higher CYR61 and 
CTGF gene expression (Figure 26I,J). 
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Figure 26: Caveolae inhibit YAP/TAZ activity. 
A:  Western blot analysis of cell lysates from U2OS control (shCon) and CAV1 
KD (shCAV1) cells. GAPDH served as loading control. Depending on the protein 
tested n ≥ 2. B-D: CLSM images of cultures of f ixed U2OS shCon (in B), mixed 
shCon and shCAV1 (in C) or mixed shCon and shCAVIN1 (in D) cells labelled for 
CAVIN1 (green), CAV1 (red) and counterstained with DAPI (blue). Arrows 
indicate CAV1 or CAVIN1 KD cells. Scale  bars = 20µm. E: CLSM images of mixed 
cultures of f ixed U2OS shCon and shCAV1 cells labelled for CAV1 (red), 
YAP/TAZ (green) and counterstained with DAPI (blue). Arrows indicate CAV1 KD 
cells. Scale bar = 20µm. F: Quantif ication of nuclear to cytoplasmic ratio of 
YAP/TAZ signal in images as in B. Each dot represents one cell, mean ± SEM.  n 
≥ 100. G: Western blot analysis of cell lysates f rom U2OS shCon and three 
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independent shCAV1 cell l ines showing increased CYR61 protein expression in 
shCAV1 cells. n ≥  2. H: Quantif ication of relative CYR61 protein levels from 
Western blot in G, normalised to the loading control HSP90. T-test, mean ± SEM. 
I and J: RT-qPCR analysis of expression of established YAP/TAZ target genes 




The induction of YAP/TAZ activity (nuclear localisation) was reversed upon re-
introduction of CAV1 into U2OS CAV1 KD cells (Figure 27A). The nuclear to 
cytoplasmic ratio of YAP/TAZ was reduced in CAV1 KD cells expressing CAV1-GFP 
(Figure 27B) and protein levels as well as mRNA expression of CYR61 and CTGF 
decreased as a result of re-expression of CAV1 (Figure 27C,D). In addition, CAV1 re-
expression also rescued CAV2 and CAVIN1 expression (Figure 27E,F). Notably, both 
CAV1 and CAVIN1 are required for the stability of the caveolin/cavin complex [102, 
103, 105]. The loss of one of the components therefore causes destabilisation of the 
other caveolae components [102, 122, 125]. In summary, CAV1 acts as a negative 
regulator of YAP/TAZ activity in U2OS cells. To further verify caveolar components 
as inhibitors of YAP/TAZ activity, shRNA-induced KD of CAV1 and CAVIN1 was 
examined in HEK 293A cells. The deficiency of only one of the central caveolar 
elements, CAV1 or CAVIN1, was sufficient to increase YAP/TAZ activity and CYR61 
protein expression (Figure 27G). Furthermore, RT-qPCR analysis of two independent 
HEK 293A shCAV1 cell lines confirmed that caveolae deficiency led to increased 
expression of YAP/TAZ target genes (Figure 27H). Consequently, these data suggest 
that caveolae function as upstream negative regulators of YAP/TAZ activity.  
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A:  CLSM image of a mixed culture of U2OS shCAV1(#1) cells expressing a 
control construct or CAV1-GFP. Cells were fixed and labelled for GFP (green), 
YAP/TAZ (red) and counterstained with DAPI (blue). Arrow indicates a CAV1-
GFP expressing cell. Red dash-line box highlights zoom-in images as in the right. 
Scale bar = 10 µm. B: Quantif ication of nuclear to cytoplasmic ratio of YAP/TAZ 
(Y/T) signal in cells control ( -) and CAV1-GFP expressing shCAV1 cells (as in  
A). Each dot represents one cell . T-test, mean ± SEM. n ≥ 80. C: Western blot 
analysis of lysates from U2OS shCAV1 ( -) control and CAV1-GFP (+) expressing 
cells. HSP90 served as loading control. D: RT-qPCR analysis of two of the 
establish YAP/TAZ target genes in CAV1-GFP expressing U2OS shCAV1 cells 
relative to control cells.  n ≥  2. Mann-Whitney test, mean ± SD. E and  F:  CLSM 
images of mixed cultures of U2OS shCAV1 cells expressing CAV1-GFP (+) or 
vector control (-). Cells were f ixed and labelled for GFP (green), CAV2 (red in E) 
or CAVIN1 (red in F) and counterstained for DAPI (blue). Scale bar = 10 µm. G: 
Western blot analysis of HEK 293A cells with shRNA-induced KD as indicated 
(Y/T = YAP/TAZ). HSP90 served as loading control. H: RT-qPCR analysis of two 
independent HEK 293A shCAV1 cell l ines relative to shCon.  n = 3. Mann-Whitney 
test, mean ± SD. 
 
 
4.3.2 Caveolae are Negative Regulators of YAP/TAZ 
Activity in vivo 
In order to investigate whether the inhibitory effect of caveolae was conserved in other 
systems and in vivo, YAP/TAZ activity was analysed in Cav1/Cav3 KO zebrafish, 
which lack caveolae [202]. Immunofluorescence labelling of Yap in the epidermis of 
48 hours post fertilisation (hpf) fish revealed nuclear accumulation of endogenous Yap 
in Cav1/Cav3 KO compared to background- and stage-matched WT zebrafish (Figure 
28A,B). Since Yap/Taz double-KO is lethal at a very early stage of embryonic 
development [66], it was not possible to fully verify the specificity of the anti-Yap 
antibody used here at this developmental stage. In addition, as well as to validate the 
finding above, WT zebrafish were compared to the Cav1/Cav3 KO when expressing 
the eGFP-Yap-S54A reporter. The Yap-S54A mutant is incapable of binding to Tead 
transcription factors [66]. The WT and Cav1/Cav3 KO zebrafish co-expressed the 
eGFP-Yap-S54A reporter and the nuclear marker H2A-mCherry in their epidermis. 
Imaging and quantification revealed a significant nuclear accumulation of Yap in the 
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KO compared to WT fish (Figure 28C,D). Consequently, these data substantiate the 
findings of the inhibition of the nuclear translocation of YAP by caveolae in vivo. 
Finally, the transcriptional activity of Yap/Taz in Cav1/Cav3 KO fish was compared to 
WT fish. In the KO fish mRNA levels of both well-established Yap/Taz-Tead target 
genes ctgf and cyr61 were significantly increased relative to the expression in WT 
zebrafish (Figure 28E). In conclusion, these data confirm increased activity of YAP 
upon caveolae deficiency both in vivo and across species. 
 
 
Figure 28: Caveolins are negative regulators of YAP/TAZ activity in vivo. 
A:  CLSM images of epithelial cells from WT and cav1/cav3  KO zebrafish embryos 
(at 48hpf) labelled for Hoechst (blue) and Yap (red). Scale bars = 25 µm. B:  
Quantification of nuclear to cytoplasmic ratio of YAP signal in images as in A. 
Each dot represents one cell. n ≥ 120. Mean ± SEM. C:  CLSM images of 
epidermal cells from cav1/cav3  KO and WT zebrafish embryos expressing 
epidermal eGFP-Yap S54A (Tead binding-deficient zebrafish Yap mutant) and 
H2A-mCherry (nuclear marker). Scale bars = 20 µm. D: Quantification of nuclear 
to cytoplasmic ratio of eGFP-Yap from images as in C. Each dot represents one 
cell. n > 50 from each genotype. n ≥ 80. Mean ± SEM. E: RT-qPCR analysis from 
cav1/cav3  KO zebrafish embryos (48hpf) relative WT. Mean ± SD.  B and D: 
Quantif ication performed by Carsten G. Hansen (UoE). C and E: Sample 
preparation and analysis performed by the Link lab (MCW).  
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4.3.3 CAV1 Regulates YAP/TAZ via Upstream Hippo 
Pathway Kinases 
In LATS1/2 KO cells YAP/TAZ are hyperactive (Figure 9) [196, 197]. To determine 
whether the CAV1-induced inhibition of YAP/TAZ activity is Hippo pathway-
dependent, CAV1 deficiency was induced in LATS1/2 KO cells (Figure 29A). 
Immunofluorescence labelling of YAP and CAV1 as well as RT-qPCR analysis of two 
independent HEK 293A CAV1 KD cell lines revealed that CAV1 deficiency does not 
further induce YAP/TAZ nuclear accumulation and transcriptional activity in LATS1/2 
KO cells (Figure 29B-D). In summary, these data indicate that the inhibition of 
YAP/TAZ by caveolae likely occurs via the Hippo pathway. 
 
 
Figure 29: CAV1 regulates YAP/TAZ activity via LATS1/2. 
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A:  Western blot analysis of lysates from HEK 293A LATS1/2 KO cells with or 
without shRNA-induced CAV1 KD. HSP90 served as a loading control. n ≥ 2. B:  
CLSM images of a mixed culture of HEK 293A LATS1/2KO cells with or without 
CAV1 KD. Cells were fixed and labelled for CAV1 (green), YAP (red) and 
counterstained with DAPI (blue). Arrows: CAV1 KD cells. Scale bars = 25 µm. C:  
Quantif ication of nuclear to cytoplasmic ratio of YAP signal in cells as in images 
in B. Each dot represents one cell . n ≥  120. T-test, mean ± SEM. D: RT-qPCR 
analysis of HEK 293A LATS1/2 KO cells with CAV1 KD, relative to control cells. 
ns = no signif icant difference between the groups.  n = 3. Mann-Whitney test, 
mean ± SD. 
 
 
4.3.4 CAV1 KD Induces Anchorage-independent Growth 
The ability of cells to grow in an anchor-free environment is one of the hallmarks of 
cancer [217] and has been shown to be increased in several cell lines upon YAP/TAZ 
hyperactivation [218, 219]. Culturing CAV1 KD cells in agarose led to increased 
numbers of colonies compared to control and CAV1 re-expressing cells (Figure 
30A,B). Consequently, CAV1 deficiency not only increases YAP/TAZ activity, but also 
induces the cancerous phenotype of cells with hyperactive YAP/TAZ. However, 
further confirmation by, for instance, KD of YAP/TAZ and TEADs is needed to validate 
these finding and will allow to fully evaluate, if the increased ability of anchorage-











A:  Soft agar colony 
formation assay of 
U2OS WT, CAV1 
KD and CAV1-GFP 
expressing CAV1 
KD cells. Images of 
crystal violet-
stained cell 
colonies in agar. 
Scale bars = 500 
µm. 
B: Quantif ication of 




n = 2. Kruskal-
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4.4 Caveolae Facilitate YAP/TAZ-mediated Flow 
Response 
Both the Hippo pathway and caveolae are known to regulate and transduce cellular 
responses to shear stress [193, 194, 220, 221]. Caveolae are recognised as 
mechanosensors and protectors and have been shown to flatten out under severe 
shear stress, which protects from membrane rupture [110]. Similarly, YAP/TAZ 
activity is induced upon mechanical stimuli, including shear stress [194, 220, 222]. 
Consequently, I aimed to determine whether caveolae and the Hippo pathway are 
mechanistically linked in the response to mechanical stimuli. 
 
4.4.1 Shear Stress induces YAP/TAZ Activity 
Confluent HEK 293A WT and YAP/TAZ KO cells were cultured at two different flow 
rates (2.1 and 4.7x10-5 Dyn/cm2) for 18 hours and compared to steady state (0 
Dyn/cm2) cell cultures. WT cells experiencing shear stress showed decreased YAP 
phosphorylation, indicating an activation of YAP upon increased flow rates (Figure 
31A). Moreover, on total proteins levels, an increase of CYR61 expression was 
evident (Figure 31B), verifying that shear stress-induced YAP/TAZ activity in the 
system used here. As expected, no CYR61 was detected in YAP/TAZ KO cells even 
under high flow rates, confirming CYR61 as an appropriate marker for YAP activation 
in this system (Figure 31B). Since 2.1x10-5 Dyn/cm2 is within the physiological range 
[189, 223], and sufficient to induce YAP/TAZ activation, all following experiments were 
performed at this flow rate. A further indication that shear stress induces YAP activity 
was provided by immunofluorescence images of WT cells experiencing flow, which 
showed a significant increase of nuclear YAP compared to cells cultured at steady 
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state (Figure 31C,D). Finally, RT-qPCR analyses revealed that shear stress indeed 
inducted YAP/TAZ activity as both CTGF and CYR61 mRNA levels were significantly 
elevated (Figure 31E). 
 
 
Figure 31: Shear stress-induced YAP/TAY activity. 
A:  Western blot based on a PhosTag SDS-gel blotted for YAP of lysates from 
HEK 293A WT cells cultures at steady state (0 Dyn/cm 2), or under f low (2.1 or 
4.7x10 -5  Dyn/cm2) and YAP/TAZ#1 (Y/T) KO cells experiencing 4.7x10 -5 Dyn/cm2.  
n = 1. B:  Western blot analysis of lysates as in A. C: CLSM images of HEK 293A 
WT cells cultures at steady state ( -) of 2.1x10 -5  Dyn/cm2 (+). Cells were fixed 
straight immediately after stopping the exposure to f low and labell ed for YAP 
(green) and CAV1 (red). Scale bar = 20 µm. D: Quantif ication of nuclear to 
cytoplasmic ratio of YAP signal in cells as in C. Each dot represents one cell . n 
≥ 100. T-test, mean ± SEM. E:  RT-qPCR analysis of expression of two YAP/TAZ 
target genes by HEK 293A WT cells cultured at 2.1x10 -5  Dyn/cm2, relative to cells 
experiencing no shear stress.  n ≥ 5. Mann-Whitney test, mean ± SD. 
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4.4.2 Shear Stress Response of YAP/TAZ is Diminished 
in CAV1-deficient Cells 
In order to determine whether the shear stress-induced activation of YAP/TAZ is 
mediated via caveolae, CAV1-deficient cells were cultured in the flow system. KD of 
CAV1 led to an increase of CYR61 expression at steady state (no shear stress (-)) 
(Figure 32A). However, under flow conditions the fold induction of CYR61 protein 
expression was significantly reduced in CAV1 KD cells (by 40%) compared to control 
cells (Figure 32B). Moreover, also shear stress-induced CTGF and CYR61 was less 
pronounced in CAV1 KD compared to control cells (Figure 32C). In order to verify 
those results, HEK 293A CAV1 KO cell lines were generated (Figure 32D). The KO of 
CAV1 resulted in a reduction of CAVIN1 (Figure 32D) and shows, as demonstrated 
above, that the stability of CAVIN1 depends on CAV1. In detail, the CAV1 KO cell 
lines showed a strong reduction of CAVIN1 signal compared to WT cells, both on total 
protein as well as single cell level, as seen by immunofluorescence assays (Figure 
32D,E). Furthermore, as in KD cells, the CAV1 KO led to YAP hypo-phosphorylation, 
shown here in two independent CAV1 KO cell lines (Figure 32F), which goes along 
with the nuclear accumulation of YAP as a result of lack of caveolae (Figure 32G). 
Interestingly, when the CAV1 KO cells experienced shear stress the nuclear to 
cytoplasmic YAP ratio was less induced compared to WT cells (Figure 32H). Meaning, 
shear stress does not increase nuclear translocation of YAP to the same extent in 
CAV1-deficient cells as in the WT. These results are coherent with RT-qPCR data 
revealing a less pronounced induction of expression of the YAP/TAZ-TEAD target 
genes CTGF and CYR61 upon flow sensing in CAV1 KO cells (Figure 32I). In 
conclusion, the induction of YAP activity, as a response to shear stress, was inhibited 
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Figure 32: Flow-induced YAP/TAZ activity blunted under CAV1 deficiency. 
A:  Western blot analysis of HEK 293A shCon and shCAV1 cells cultured at 
steady state (-) and 2.1x10 -5 Dyn/cm2 (+). n ≥ 1. B: Quantif ication of CYR61 
protein levels in shCon and shCAV1 cells as in A.  n ≥ 3. C: RT-qPCR analysis of 
the relative fold induction of YAP/TAZ target genes expression in shCAV1 upon 
flow compared to control cells. n ≥  5. Mann-Whitney test, mean ± SD. D:  Western 
blot analysis of three independent HEK 293A CAV1 KO cell lines and WT cells. 
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n ≥ 1. E: CLSM images of HEK 293A WT and two of the CAV1 KO cell l ines. Cells 
were f ixed and labelled for CAV1 (red), CAVIN1 (green) and counterstained with 
DAPI (blue). Scale bar = 30 µm. F: Western blot based on a PhosTag SDS-gel 
probing for YAP protein of lysates as in D. G: Quantif ication of the ratio of nuclear 
to cytoplasmic YAP in cells cultured at steady state. Each dot represents one 
cell. n ≥  120. T-test, mean ± SEM. H:  Quantif ication of nuclear to cytoplasmic 
ratio of YAP signal displayed as normalised flow -induced values. Each dot 
represents one cell. n ≥ 100. T-test, mean ± SEM. I:  RT-qPCR analysis of cells 
experiencing shear stress presented as relative fo ld induction of target gene 
expression in two separate CAV1 KO clones upon flow compared to control cells.  
n = 3. Mann-Whitney test, mean ± SD. 
 
 
4.4.3 Re-expression of CAV1 Restores YAP/TAZ 
Response to Shear Stress 
In order to further validate the above results, CAV1 was re-introduced into CAV1 KO 
cells (Figure 33A). Under steady state conditions the dependency of CAVIN1 stability 
on CAV1 expression was further confirmed [102, 105, 125]. In both generated CAV1 
re-expressing cell lines the expression of CAVIN1 increased compared to the CAV1 
KO parental cell lines (Figure 33A-C), highlighting that exogenous CAV1 is functional, 
as it stabilises CAVIN1 protein. Importantly, the re-introduction of CAV1 also modified 
YAP/TAZ expression. In both CAV1 re-expressing cell lines the ratio of nuclear to 
cytoplasmic YAP/TAZ was reduced compared to CAV1 KO cells (Figure 33D-G). In 
terms of the shear stress response, re-expression of CAV1 facilitated the flow-induced 
YAP/TAZ activation, resulting in increased nuclear YAP/TAZ (Figure 33H,I). In 
conclusion, these data show that shear stress-induced YAP/TAZ activation is, at least 
partly, mediated via caveolae. 
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Figure 33: Re-expression of CAV1 restores YAP/TAZ response to shear stress. 
A:  Western blot analysis of HEK 293A WT and two independent CAV1 KO cel l 
l ines expressing vector control or CAV1 GAPDH served as a loading control. n ≥  
1. B and C: CLSM images of CAV1 KO cell l ines (#1 and #2) expressing vector 
control (+empty vector) or CAV1. Cells were fixed and labelled for CAV1 (red), 
CAVIN1 (green) and counterstained with DAPI (blue). Scale bar = 30 µm. D and 
E:  CLSM images of mixed cultures of CAV1 KO and CAV1 re-expressing cells, 
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f ixed and labelled for CAV1 (red), YAP (green) and counterstained with DAPI 
(blue). Scale bar = 25 µm. F and G: Quantif ication of YAP/TAZ (Y/T) nuclear to 
cytoplasmic ratio in mixed steady state cultures of HEK 293A CAV1 KO (#1 and 
#2) vector control and CAV1 re-expressing cells. H and I: Quantif ication of fold 
induction of nuclear to cytoplasmic YAP/TAZ as in F and G of cells experiencing 
shear stress. Averages were normalised to steady state conditions. F-I: Each dot 
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4.5 Initial Characterisation of Blood Outgrowth 
Endothelial Cells (BOEC) 
In the future, the results above should be complemented with additional physiological 
relevant systems. Therefore, I initiated the development of a primary cell derived 
endothelial cell line, which preserves its endothelial character over several passages. 
Endothelial progenitor cells were isolated from human blood and differentiated into 
blood outgrowth endothelial cells (BOECs), following the protocol established by 
Ormiston, et al. [198]. At passage 0 (after differentiation) the cells were labelled for 
endothelial markers VE-Cadherin and PECAM1 and compared to HEK 293A WT cells 
(Figure 34A). The BOECs but, as expected, not HEK 293A cells expressed both 
endothelial markers. To further establish these cells as a powerful endothelial in vitro 
system, I analysed the expression of endothelial markers at passage 9 (Figure 34B). 
Both VE-Cadherin and PECAM1 were strongly expressed throughout the culture. 
Moreover, cells showed expression of both YAP and TAZ. 
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Figure 34: BOECs stably express endothelial markers. 
A:  CLSM images of HEK 293A and BOECs (passage 0). Cells were fixed and 
labelled for PECAM1 (green), VE-Cadherin (red) and counterstained with DAPI 
(blue). B: CLSM images of BOECs (passage 9), f ixed and labelled for PECAM1 
or VE-Cadherin (green), YAP or YAP/TAZ (red) and counterstained with DAPI 
(blue). Scale bars = 50µm. n = 1. 
 
 
Also, on total protein levels, assayed by Western blotting, both endothelial markers 
were detected in BOECs, while the epithelial cell line was negative for PECAM1 and 
VE-Cadherin (Figure 35). Preliminary analysis of total protein levels of Hippo pathway 
(target) and caveolar proteins revealed an active Hippo pathway. However, it appears 
that TAZ covers a more significant role than YAP in BOECs, as it is higher expressed 
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compared to YAP. As a (most likely specific) YAP signal was detected by IF and a 
signal for unphosphorylated (active) YAP was obtained by Western blotting, the 
absence of total YAP signal may be explained by the use of unsuitable, YAP-specific 
antibodies or insufficient exposure while Western blotting. Furthermore, BOEC 
express the central caveolar components CAV1 and CAVIN1 stronger compared to 




Finally, to further analysed the potential heterogeneity of cultures, the expression of 
the endothelial markers as well as CAV1 expression was established on single cell 
basis at passage 11. By flow cytometry analysis separate populations of BOEC and 
HEK 293A cells were labelled with VE-Cadherin, PECAM1 and CAV1, respectively. 
The populations were gated (Figure 36A,B) for cells, single cells and live cells. 
Figure 35: BOECs have a 
functional Hippo pathway and 
express essential caveolar 
components. 
Western blot analysis of HEK 
293A and BOECs (passage 9). 
Active YAP is an antibody 
specif ic to unphosphorylated 
YAP. HSP90 was used loading 
control. Please note that the 
absence of (CTGF, CAV1, 
CAVIN1) signal in HEK 293A is 
most l ikely due to a lower 
protein expression, which 
required a more extended 
exposure than the one chosen 
here. n = 1. 
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Labelling with Zombie aqua (live/dead marker) revealed a viability of about 95% in 
HEK 293A and 80% in BOEC (Figure 36A,B). 
 
 
Figure 36: Gating strategy. 
Flow cytometry analysis of HEK 293A cells and BOECs at passage 11. Gating 
strategy for HEK 293A (A) and BOECs (B). From left to r ight: Cells, single cells, 
l ive cells ( identif ied by Zombie aqua labelling). Numbers in each graph indicate 
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Figure 37: BOECs retain endothelial markers over many passages. 
A:  Flow cytometry analysis of HEK 293A WT cells. Percentages of l ive cells, 
cells labelled with secondary antibody only (2°), PECAM1, CAV1 and VE-
Cadherin labelled cells. Labelling indicates the quadrant of posit ive cells per 
condition. Live cells are relative to single cells. All other conditions are relative 
to live cells. B:  Histogram of detected cells incubated with anti -mouse secondary 
antibody only (grey) and anti-PECAM1 (antibody raised in mouse, blue). C: 
Histogram of detected cells incubated with ant i-rabbit secondary antibody only 
(grey) and anti-VE-Cadherin (antibody raised in rabbit, blue) and anti -CAV1 
(red). D:  Flow cytometry analysis as in A but of BOECs. E and F:  Histogram as 
in B and C but of BOECs. n = 1. 
 
 
Both cell lines express CAV1, while BOECs express more CAV1 than HEK 293A 
indicated by the right shift (Figure 37C,F), which is consistent with the bulk analysis in 
the Western blot above (Figure 35). The secondary antibodies both showed low 
unspecific binding, as shown by the controls incubated with secondary antibody only 
(Figure 37A-F). At the same time, the specificity of the VE-Cadherin and the PECAM1 
antibodies was evident from the low signal in epithelial cells. The comparison between 
the secondary-only treated HEK 293A cells (anti mouse, anti-rabbit) and the cells 
incubated with the combination of primary antibody against each of the endothelial 
markers (VE-Cadherin, PECAM1) and secondary antibody showed a high overlap 
(Figure 37B,C). Consequently, the HEK 293A cells were negative for both VE-
Cadherin (0.34% positive of live cells) and PECAM1 (0.088% positive of live cells) 
expression (Figure 37A-C). BOECs on the other hand, highly expressed both 
endothelial markers VE-Cadherin (78.2% of live cells) and PECAM1 (84.5% of live 
cells, despite the suboptimal gating for PECAM1) (Figure 37D-F). There was a clear 
shift between the cells labelled for the endothelial markers compared to cells only 
incubated with the secondary antibodies (Figure 37E,F). The comparison between 
HEK 293A and BOECs underlines their endothelial character of the blood outgrowth 
endothelial cells and verifies that they stably express endothelial markers even at 
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passage 11. These data are exploratory, however, they emphasise that BOECs are 
a promising model to verify the physiological role and provide further mechanistic 














The Hippo pathway is widely recognised as a major driving force in multicellular, 
homeostatic and developmental processes [71, 212-214, 224-226]. Due to its central 
role, a tight regulation of the Hippo pathway is critical. A variety of regulatory 
mechanisms and feedback loops have been discovered. However, new findings 
constantly add novel interaction partners and feedback processes, emphasising that 
the understanding of Hippo pathway regulation is not yet complete [21, 58, 60, 84]. 
An accumulating number of studies show the role of the Hippo pathway in 
mechanotransduction and interactions with plasma membrane elements [79, 227-
229]. A plasma membrane organelle, which is an important mechansosensor and 
protector are caveolae [109, 140, 173]. One stimulus that both the Hippo pathway and 
caveolae respond to is shear stress [171, 193, 194, 220]. Flow sensing plays major 
roles in multiple cell types especially during development [189, 223], in the 
cardiovascular system [223] or in the kidney [189]. Caveolae are enriched in cells 
experiencing shear stress, e.g. endothelial cells, and caveolae evolved to be 
important integrators of mechanical stimuli in those cells [168, 171, 230-232]. So far, 
the mechanistic insights into how the Hippo pathway is regulated by shear stress and 
how this cellular response is conferred has been limited [194, 220]. Due to the fact 
that both the regulation of caveolae and the Hippo pathway are still not fully 
understood, the question arose whether caveolae might influence the Hippo pathway, 
which further regulates the cellular response to mechanical stress. This work aimed 
to broadening the understanding of Hippo pathway regulation. Therefore, the potential 
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The key transcription co-activators of the Hippo pathway, YAP and TAZ, are known 
to activate transcription of genes central for proliferation and cell survival [22, 70, 197, 
233]. Examining YAP/TAZ KO cells, in terms of expression of essential caveolar 
components, showed a strong reliance of key caveolae elements on the presence of 
YAP and TAZ activity. At the time these studies were undertaken, the relation between 
caveolae and Hippo pathway components was not known. Only recently, a study 
focusing on the interaction between YAP and CAV1 also identified that the expression 
of most YAP/TAZ target genes positively correlates with CAV1 expression [234]. 
However, we were the first to confirm that the expression of essential caveolar 
components depends on YAP/TAZ activity in different cell lines and species, and that 
CAV1 and CAVIN1 are direct target genes of YAP-TEAD1 [195]. Notably, YAP/TAZ 
hyperactivity only slightly increases CAV1 and CAVIN1 expression, while YAP/TAZ 
KO results in drastic loss of caveolae. Therefore, YAP/TAZ are essential for caveolae 
expression, though their activity appears not to be sufficient for CAV1 and CAVIN1 
expression. Other factors that are regulating YAP/TAZ-TEAD activity are VGLL4, 
MRTF-SRF, AP-1 and SWI/SNF [27, 235-240] and might also play roles in regulating 
gene expression of caveolar components. Consequently, further studies are needed 
to identify the details of the expression of essential caveolar components and what 
roles the Hippo pathway and YAP/TAZ hyperactivation play in the regulation of 
caveolae expression. 
The complexity of Hippo pathway regulation was revealed by identifying the negative 
feedback loop CAV1 and CAVIN1 exhibit on YAP/TAZ activity. YAP/TAZ induce the 
expression of CAV1 and CAVIN1, while caveolar components are inhibitors of 
YAP/TAZ activity. Loss of caveolae leads to the inactivation of the Hippo pathway 
kinase cascade and YAP/TAZ activation. As both caveolae and the Hippo pathway 
play central roles in metabolic signalling [103, 197, 241-244], regeneration [67, 245], 
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and cancers [214, 246], this negative feedback mechanism has the potential to be 
subject of new therapeutic approaches. One aspect that merits highlighting is that 
loss-of-function mutations within the muscle specific CAV3 as well as of CAVIN1 
cause muscular dystrophy [109, 142, 247-249]. The Hippo pathway is a potent 
regulator of muscle cells [250-254] and intriguingly there are overlapping gene sets 
between those upregulated in muscular dystrophy caused by CAVIN1 or CAV3 
mutations and those driven by muscular YAP/TAZ-TEAD transcription [142, 249-254]. 
It might therefore be worth pursuing to examine the state of the Hippo pathway within 
caveolae-deficient muscular dystrophy patients. Targeting the Hippo pathway within 
these patients may allow for therapeutic intervention [225, 226, 255, 256].  
Another aspect where the YAP/TAZ and caveolae interplay is likely be identified as 
an important mechanism is cancer. Deregulation of Hippo pathway components and 
YAP/TAZ hyperactivity play key roles in carcinogenesis and cancer progression [201, 
257, 258]. Upregulation and activation of YAP/TAZ is a general phenomenon in most, 
if not all solid tumours, including colon, lung and liver carcinoma [71, 259]. Similarly, 
caveolae have been shown to play roles in cancer [143-145, 260]. Here, CAV1 KD 
was sufficient to increase the ability of U2OS cells to grow in an anchor-independent 
environment, a characteristic of cancer cells [217]. Nonetheless, the role of caveolae 
in cancer is regarded as cell type and cancer specific as in some cancers CAV1 is 
upregulation while in other cancers it is downregulated [261]. Therefore, studies 
targeting the interplay between the Hippo pathway and caveolae have to determine 
the role of this interaction in carcinogenesis, cancer progression and metastasis in a 
cancer type specific manner. What is undebatable however, is the role caveolae play 
in neovascularisation and angiogenesis, which are further hallmarks of cancer [172, 
217, 260, 261]. Also the role of the Hippo pathway in angiogenesis has been widely 
identified [222]. CAV1 deficiency promotes angiogenesis via induction of the nitric 
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oxide pathway or VEGF expression, while active YAP/TAZ promote proliferation, 
survival and migration of endothelial cells to promote angiogenesis [222, 262-264]. 
The vessel-lining endothelial cells are central for angiogenesis [77, 173, 188, 265]. 
These cells are constantly exposed to mechanical forces, in particular shear stress 
[165, 190]. So far, the mechanistic insights into how the Hippo pathway is regulated 
by shear stress and how this cellular response is conferred, has been limited [194, 
220]. Caveolae have been reported to mediate shear stress stimuli into the cell [173, 
193]. However, how caveolae perform mechanotransduction and the response to 
shear stress in particular, is not well understood [98, 171, 173, 174, 193, 202, 266]. 
Hence, the final objective of this thesis was to identify, if the newly establishing link 
between the Hippo pathway and caveolae plays a role in the shear stress response. 
The flow system used here induced expression of CTGF and CYR61 in WT cells, 
which is in agreement with previous studies [267, 268]. Significantly, the results 
obtained reveal that shear stress-mediated induction of these YAP/TAZ-TEAD target 
genes is caveolae-dependent. So far, there is no complete and detailed mechanistic 
understanding of this process. However, the caveolae-dependent regulation occurs 
via LATS-mediated inhibitory phosphorylation of YAP/TAZ. 
Caveolae are known to protect cells from mechanical stress [109, 173, 174, 193, 202, 
266, 269]. Major insights into the composition of caveolae have been facilitated by the 
identification of additional caveolar proteins, like CAVINs [103-105, 120, 125, 270], 
PACSINs [126, 130] and EHDs [102, 126-128, 270, 271]. In combination with the 
recent technical advancement in EM and biophysical technologies, these discoveries 
have allowed impressive and detailed understanding into the molecular composition 
of caveolae [102-104, 120, 125, 270, 272-275]. Nonetheless, how caveolae gene 
expression is regulated as well as how they mediate flow sensing to the interior of the 
cell demand further investigations [101, 109, 173, 174, 193, 202, 266, 269]. Still, the 
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data presented here highlight that YAP/TAZ are activated in caveolae-deficient cells, 
and that these cells are therefore insensitive to shear stress mediated YAP/TAZ 
activation, which indicates caveolae and the Hippo pathway as a cardinal nexus for 
cellular flow sensing. 
In order to verify the caveolae-dependent YAP/TAZ activation in a more physiological 
system than epithelial cells, primary cell derived endothelial cell lines were generated. 
The protocol established by Ormiston, et al. [198] allowed the isolation of endothelial 
progenitor cells from human blood which were then differentiated into endothelial 
cells. Those blood outgrowth endothelial cells (BOECs) stably express endothelial 
markers throughout many passages which is promising, considering other established 
endothelial in vitro models. The HUVEC (Human umbilical vein endothelial cells) line 
for example is costly and does not stably express endothelial markers over many 
passages, which limits their applicability for genetic and functional studies [276-278]. 
The BOEC line generated here appears stably expressing endothelial markers 
PECAM1 and VE-Cadherin, though evaluation of later passages is required to confirm 
its stability. BOECs therefore appear to offer a reliable model to investigate the Hippo 
pathway and caveolae interaction in an endothelial system. 
BOECs will further allow to elucidate possible changes of VE-Cadherin expression in 
the context of Hippo pathway and caveolae interaction. VE-Cadherin locates at the 
junctions of vascular endothelial cells, where it mediates adhesion and regulates 
vascular permeability and leukocyte extravasation [279]. It will be interesting to 
evaluate if endothelial barrier functions are affected and the expression of VE-
Cadherin is changed upon YAP/TAZ deficiency-induced caveolae reduction. It has 
been shown that CAV1 interacts with VE-Cadherin/catenin complexes at cell junctions 
and that VE-Cadherin expression is reduced in CAV1-deficient cells [231, 280]. Still, 
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endothelial barrier integrity was not affected in those cells under unstimulated 
conditions. However, thrombin stimulation increased the paracellular permeability in 
a CAV1-dependent manner [231]. Thrombin further induces YAP/TAZ activity in an 
epithelial cell model [281]. Consequently, it is worth investigating if thrombin disrupts 
the endothelial barrier integrity and if this process is mediated via the YAP/TAZ and 
CAV1 axis.  
Moreover, hypertension is another aspect where the newly discovered link between 
the Hippo pathway and caveolae might be important and potentially opens new 
therapeutic approaches. Caveolae deficiency induces hypertension [140, 170, 282, 
283]. It is speculative, however caveolae deficiency-induced YAP/TAZ hyperactivity 
might be a self-regulatory mechanism. YAP/TAZ-induced expression of caveolar 
components might be a compensatory route to protect vessels from increased force 
they are exposed to in hypertension. Verifying how YAP/TAZ and caveolae are 
regulated in the context of hypertension might open up new points of action to treat 
hypertension. 
Finally, it is important to mention that somewhat contradicting to the findings 
discussed here, a recent study identified CAV1 as a YAP activator [234]. CAV1 
deficiency led to the cytoplasmic retention of YAP and decreased YAP/TAZ target 
gene expression in mouse embryonic fibroblasts (MEF) and MDA-MB-231 cells in a 
LATS1/2-independent manner [234]. These results highlight the complexity and 
context dependency of the Hippo pathway. So far, details of how YAP/TAZ and 
caveolae interact are not fully understood. The interplay is likely to be cell type and 
context dependent and might involve yet unidentified regulators which govern the 
manifestation of this interaction.
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6. Future Directions 
 
The interplay between the Hippo pathway and caveolae has the potential to be of 
therapeutic importance. To fully take advantage of this potential, further lines of 
research are needed to gain additional and detailed insights into the molecular 
mechanisms and conservation across cell types and disease states. 
The established BOEC line is a promising model to investigate the relationship 
between the Hippo pathway, YAP/TAZ and caveolae in human primary cell derived 
endothelial cells and therefore in a physiological and therapeutically relevant context. 
The caveolae-rich endothelium lines blood vessels and is therefore constantly 
exposed to shear stress. Thus, the first step should be to validate the results obtained 
here in the generated endothelial cell lines, BOEC. Furthermore, KD and/or KO BOEC 
lines of central Hippo pathway and caveolar components will provide powerful tools 
to study details of this interplay. Preliminary results revealed that KD of CAV1 is 
possible and it affects CAVIN1 expression as predicted. These results require further 
validation, though they are promising in the prospect of the feasibility of generating 
KD and potentially KO cell lines to study the interaction of the Hippo pathway and 
caveolae both at steady state and under shear stress conditions. 
Initial attempts to study the shear stress response of BOECs were not successful, 
however they still revealed that it is possible to culture those endothelial cells in the 
Quasi Vivo flow system. I am confident that under appropriate conditions it will be 
possible to evaluate the interplay between the Hippo pathway and caveolae and their 
shear stress response in this system. As the flow rates in the Quasi Vivo setup are 
variable, it provides the opportunity to study the response to different share stress 
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strengths. Possibly, by culturing cells at high flow rates or infarction by disrupting the 
medium flow and/or starving cells from nutrients, high blood pressure may be 
simulated to provide valuable insights into the Hippo pathway and caveolae under 
these pathological conditions. 
Moreover, the protocol of Ormiston, et al. [198] opens the opportunity to isolate 
endothelial progenitor cells from patients with CAV1 or CAVIN1 deficiency. However, 
these CAV1 and CAVIN1-deficient patients are rare [140, 142, 284], and so patient 
material might be challenging to obtain. Yet, obtaining patient material from either 
aged or other patient groups is feasible and could provide insight into the aged-
dependency of the differentiation potential, YAP/TAZ activity and caveolar component 
expression patterns. Likewise, it will be of interest to determine if there are differences 
in YAP/TAZ and caveolae activity and expression in progenitors from patients with 
hypertension, for example. Still, epigenetic changes during the differentiation process 
might impair the relevance of studying these patient-derived endothelial cells in vitro, 
which need to be considered. However, investigating cells from different background, 
in terms of their differentiation capacity and their activity levels of YAP/TAZ during this 
process, will provide further insights into the impact and relevance of the Hippo 
pathway and caveolae interaction in development. 
In the future, the combination of the blood endothelial progenitor cells and the Quasi 
Vivo flow system may allow to investigate the changes in expression levels of Hippo 
pathway and caveolar components during cell differentiation in the context of shear 
stress exposure. Comparing these data with cells originating from patients with 
caveolae related mutations offers the possibility to elucidate potential dependences 
of endothelial differentiation and the response of Hippo pathway during differentiation 
in a caveolae-deficient background. Finally, although technically challenging, it might 
be worth aiming to induce KD of Hippo pathway or caveolar components by lentivirus-
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mediated shRNA transduction of progenitor cells of healthy donors. If successful, 
those cells will provide important data on expression patterns of Hippo pathway and 
caveolar components during differentiation at steady state and under shear stress. 
Apart from the Quasi Vivo system, the relationship between the Hippo pathway and 
caveolae could be investigated in 3D cultures. 2D cultures have their limitations [285, 
286] and both the Hippo pathway and caveolae are sensitive to mechanical stimuli 
[77, 78, 82, 97, 111, 195, 234]. The response to different ECM compositions, 
investigated in 3D cultures, e.g. by hydrogels of different stiffnesses, would provide 
additional understanding of the interplay between the Hippo pathway and caveolae. 
Following the findings reported in this thesis it is plausible that ECM stiffening induced 
activation of YAP/TAZ might increases caveolar gene expression. Verifying this 
response is of interest in the field of cancer research, for example, as stiffness within 
a tumour changes during cancer progression [76].  
In order to investigate if the YAP/TAZ deficiency-induced reduction of caveolae 
indeed impairs the integrity of the endothelial barrier, transendothelial electrical 
resistance (TEER) measurements may be performed. Using for example the Electric 
Cell-substrate Impedance Sensing (ECIS) system and compare potential differences 
in TEER of BOEC WT and KD or KO cell lines will provide insights into the 
permeability of YAP/TAZ-deficient cells. Exploring alterations in the endothelial layer 
will provide insight into knock-on effects of Hippo pathway-regulated caveolae 
deficiency. Moreover, a biochemical analysis of CAVIN and caveolae complexes in 
these caveolae-rich endothelial cells under flow and in KD or KO cells might also 
reveal important mechanistic insights. 
Interestingly, overexpression of CAV1 induces endothelial tube formation [232], which 
stands in contrast to other studies, which reported an inhibition of CAV1-induced 
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vessel formation [287]. Consequently, the function of CAV1 in angiogenesis is yet to 
be fully elucidated and the BOEC model has the potential to enhance our 
understanding of angiogenic processes and what role caveolae and the Hippo 
pathway and their interaction play in this context. 
In conclusion, the list of further investigations is not exhaustive. Detailed insights into 
the regulatory interaction of the Hippo pathway, caveolae and their role in shear stress 
response is yet to be fully obtained. Nevertheless, the findings discussed in this thesis 
pave the way to further exploration of caveolae as a link, that explains some of the 
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